Tricyclic pyrimidinone compounds, and preparation method, pharmaceutical composition and application thereof

A novel tricyclic pyrimidone compound functions as an Lp-PLA2 inhibitor, addressing the inadequacies of current treatments for neurodegenerative and cardiovascular diseases by reducing oxidative stress and inflammation, thereby offering a therapeutic solution for Alzheimer's disease, glaucoma, age-related macular degeneration, atherosclerosis, diabetic macular edema, and prostate diseases.

CN119080800APending Publication Date: 2024-12-06SHANGHAI SHENSHI WISE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411229161.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-01-17
Filing Date
2024-09-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases such as Alzheimer's disease, glaucoma, age-related macular degeneration, cardiovascular diseases like atherosclerosis, and diabetic macular edema, as well as prostate diseases, are inadequate due to the lack of effective inhibitors for lipoprotein-associated phospholipase A2 (Lp-PLA2), which contributes to oxidative stress and inflammation.

Method used

Development of a novel tricyclic pyrimidone compound and its pharmaceutically acceptable salts, acting as potent Lp-PLA2 inhibitors, to target and reduce the activity of Lp-PLA2, thereby mitigating oxidative stress and inflammation associated with these diseases.

Benefits of technology

The tricyclic pyrimidone compounds effectively inhibit Lp-PLA2, providing therapeutic benefits for neurodegenerative diseases, cardiovascular diseases, and prostate diseases by reducing oxidative stress and inflammation, thus offering a promising treatment approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080800A_ABST
    Figure CN119080800A_ABST
Patent Text Reader

Abstract

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used for treating neurodegenerative related diseases, such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), cardiovascular diseases including atherosclerosis and the like, diabetic macular edema (DME), prostate diseases and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine, and specifically relates to a tricyclic pyrimidone compound, a preparation method thereof, a pharmaceutical composition thereof, and its use in medicine. In particular, the present invention relates to a tricyclic pyrimidone derivative, a preparation method thereof, a pharmaceutical composition containing the derivative, and its use as an Lp-PLA2 inhibitor for treating neurodegenerative diseases such as Alzheimer's disease, glaucoma, age-related macular degeneration (AMD), cardiovascular diseases such as atherosclerosis, diabetic macular edema, or prostate diseases. Background Art

[0002] Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 superfamily (Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Chem Rev. 2011, 111, 6130-6185). It is mainly secreted by monocytes, macrophages, T lymphocytes and chief cells (Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. J Biol Chem. 1990, 265: 9682-9687; Nakajima K, Murakami M, Yanoshita R, Samejima Y, Karasawa K, Setaka M, Nojima S, Kudo IJ Biol Chem. 1997, 272, 19708-19713). Phosphatidylcholine sn-2 ester is produced during the oxidation of low-density lipoprotein (LDL), and Lp-PLA2 is responsible for hydrolyzing oxidatively modified phosphatidylcholine sn-2 ester, and then producing oxidized fatty acids and lysophosphatidylcholine (LysoPC) (Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Atherosclerosis. 2000, 150, 413-419; MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM. Biochem J. 1999, 338, 479-487). Oxidized fatty acids and LysoPC both play a role in activating macrophages, increasing oxidative stress, affecting T lymphocyte function and inducing inflammatory responses (Quinn MT, Parthasarathy S, Steinberg D. Proc Natl Acad Sci US A. 1988, 85, 2805-2809). LysoPC is reported to induce the release of a variety of cytotoxic inflammatory cytokines (Shi, et al. Atherosclerosis, 2007, 191, 54-62). In addition, LysoPC is also involved in leukocyte activation, induction of apoptosis and mediation of endothelial dysfunction (Wilensky, et al. Current Opinion in Lipidology, 2009, 20, 415-420).

[0003] It has been reported in the literature that plasma Lp-PLA2 levels are associated with cardiovascular disease (Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C. Atherosclerosis. 2014, 235, 384-391), diabetic macular edema (DME) (Staurenghi G, Ye L, Magee MH, Danis RP, Wurzelmann J, Adamson P, McLaughlin MM, Darapladib DMESG. Ophthalmology. 2015, 122, 990-996), and prostate cancer (Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, Halgunset J. Clin Cancer Res. 2012, 18, 3261-3269).

[0004] Alzheimer's disease (AD) is a chronic neurodegenerative disease that causes cognitive decline, mood swings, irreversible memory loss, disorientation, language impairment, and loss of self-protection ability (Hardy J, et al. Science 2002, 297, 353-356). Alzheimer's disease usually starts slowly and gradually worsens over time, which is the cause of 60% to 70% of dementia cases and affects about 6% of the population over 65 years old. AD patients will gradually withdraw from their families and society, become increasingly dependent on help, and eventually progress to death. AD is one of the most expensive diseases in developed countries and is also costly in other countries. In particular, as aging becomes an important social issue, these costs will increase dramatically. There is no doubt that AD is a complex disease involving multiple factors. Although the etiology of AD has not been fully elucidated, it is clear that several factors are involved in the occurrence and development of the disease, including aggregated tau protein and Aβ peptide, oxidative stress and neuroinflammation (Echeverria V, Yarkov A, Aliev G. Prog Neurobiol. 2016, 144, 142-157). Current AD drug research and development focuses on targets of Aβ amyloidosis and tau (Chiang K, Koo EH. Annu Rev Pharmacol Toxicol. 2014, 54, 381-405; Awasthi M, Singh S, Pandey VP, Dwivedi UN. J Neurol Sci. 2016, 361, 256-271). However, despite strong preclinical data, the results of late clinical trials have so far failed to demonstrate clinical efficacy. These disappointing results indicate that other neuropathological mechanisms, such as oxidative stress and neuroinflammation, may have to be explored for AD treatment.

[0005] Elevated levels of Lp-PLA2 in plasma increase the risk of dementia, including AD (Van Oijen, et al. Annals of Neurology, 2006, 59, 139). Vascular dementia and mixed dementia, as well as high oxidized LDL levels, have been found in AD patients (Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A, Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2015, 1, 131-140; Kassner, et al. Current Alzheimer Research, 2008, 5, 358-366; Dildar, et al. Alzheimer Dis Assoc Disord, 24, April-June (2010); Sinem, et al. Current Alzheimer Research, 2010, 7, 463-469). Neuroinflammation and up-regulated inflammatory cytokines have also been found in AD patients (Colangelo, et al. Journal of Neuroscience Research, 2002, 70, 462-473; Wyss-Coray, Nature Medicine, 2006, 12, Sept.).

[0006] Based on all these findings, Lp-PLA2 is a potential target for the treatment of AD, and the clinical results of the Lp-PLA2 inhibitor Rilapladib in AD patients further confirmed this (Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A, Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2015, 1, 131-140).

[0007] Glaucoma and age-related macular degeneration (AMD) are retinal neurodegenerative diseases. Buschini et al. reported that inflammation, including TNF-α signaling, may play an important role in the pathogenesis of glaucoma and AMD (Buschini, et al. Progress in Neurobiology, 2011, 95, 14-25; Tezel, Progress in Brain Research, vol. 173, ISSN 0079-6123, Chapter 28). In addition, Shi et al. confirmed that Lp-PLA2 inhibitors can block the release of inflammatory cytokines (Shi, et al. Atherosclerosis, 2007, 191, 54-62). The inhibition of Lp-PLA2 is a potential treatment for glaucoma and AMD.

[0008] Many Lp-PLA2 inhibitors have been reported, including β-lactams (Tew DG, Boyd HF, Ashman S, Theobald C, Leach CA. Biochemistry. 1998, 37, 10087-10093), oximes (Jeong TS, Kim MJ, Yu H, Kim HS, Choi JK, Kim SS, Lee WS. Bioorg Med Chem Lett. 2005, 15, 1525-1527; Jeong HJ, Park YD, Park HY, Jeong IY, Jeong TS, Lee WS. Bioorg Med Chem Lett. 2006, 16, 5576-5579), amides of xanthuric acid (Lin EC, Hu Y, Amantea CM, Pham LM, Cajica J, Okerberg E, Brown HE, Fraser A, Du L, Kohno J Y,Ishiyama J,Kozarich JW,Shreder KR.Bioorg MedChem Lett.2012,22,868-871;Hu Y,Lin EC,Pham LM,Cajica J,Amantea CM,Okerberg E,Brown HE,Fraser A,Du L,Kohno Y,Ishiyama J,Kozarich JW,Shreder KR.Bioorg MedChem Lett.2013,23,1553-1556), and carbamates (Nagano JM, Hsu KL, Whitby LR, NiphakisMJ, Speers AE, Brown SJ, Spicer T, Fernandez-Vega V, Ferguson J, Hodder P, Srinivasan P, Gonzalez TD, Rosen H, Bahnson BJ, Cravatt BF.Bioorg Med Chem Lett. 2013, 23, 839-843).

[0009] It is reported that the Lp-PLA2 inhibitor Darapladib is a potential treatment for atherosclerosis and DME (Magrioti V, Kokotos G. Expert Opin Ther Pat. 2013; 23: 333-344).

[0010] Chinese patent application CN 113861220A discloses tricyclic pyrimidone compounds of the following formula, which can be used to treat neurodegenerative diseases and cardiovascular diseases.

[0011] Summary of the invention

[0012] The present invention provides a novel Lp-PLA2 inhibitor, which can be used to treat neurodegenerative diseases, such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), cardiovascular diseases including atherosclerosis, diabetic macular edema (DME), or prostate diseases.

[0013] The present invention provides a tricyclic pyrimidone compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

[0014]

[0015] in,

[0016] n1, n2, n3 are each independently 0, 1 or 2;

[0017] R1 and R2 are each independently H or alkyl;

[0018] X1 and X2 are each independently selected from: alkylene, -O-, -S-, or -NR'-; wherein R' is selected from: H, alkyl, deuterated alkyl, or cycloalkyl;

[0019] Ar is an arylene or heteroarylene group; the arylene or heteroarylene group is optionally substituted by 0, 1 or more substituents, each of which is independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, deuterated alkyl, deuterated alkoxy, hydroxy, hydroxyalkyl, cyano, amino, monoalkyl or dialkyl substituted amino, nitro, carboxyl, aldehyde, cycloalkyl, heterocyclyl, aryl, or heteroaryl;

[0020] Y is -H, halogen, alkyl, haloalkyl, haloalkoxy, cycloalkyl, alkoxy, deuterated alkyl, deuterated alkoxy, hydroxy, hydroxyalkyl, cyano, -OAr', -SAr', -NH-Ar', -NMe-Ar', -NHR", or -R"'-Ar'; wherein Ar' is selected from aryl or heteroaryl; the aryl or heteroaryl is optionally substituted with 0, 1 or more substituents, each of which is independently selected from halogen, alkyl, haloalkyl, alkoxy, hydroxy, hydroxyalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, halosulfanyl, cyano, amino, nitro, aldehyde, carboxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R" is alkyl or cycloalkyl; R"' is alkylene;

[0021] Z is O or S;

[0022] The halogen atoms in the “halogen”, “haloalkyl”, “haloalkoxy” and “halosulfanyl” are each independently selected from F, Cl, Br or I;

[0023] The alkyl groups in the aforementioned “alkyl”, “deuterated alkyl”, “deuterated alkoxy”, “hydroxyalkyl”, “haloalkyl”, “haloalkoxy”, “alkoxy”, and “amino substituted with monoalkyl or dialkyl” are each independently C1-C 10 linear or branched alkyl; optionally, C1-C7 linear or branched alkyl; optionally, C1-C4 linear or branched alkyl; optionally, selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, butyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl;

[0024] The "alkylene" is each independently C1-C 10 A straight or branched alkylene group; optionally, a C1-C7 straight or branched alkylene group; optionally, a C1-C5 straight or branched alkylene group; optionally, selected from methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, tert-butylene, sec-butylene, n-pentylene, 1-methylbutylene, 2-methylbutylene, 3-methylbutylene, isopentylene, 1-ethylpropylene, neopentylene, n-hexylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene 1,2-dimethylbutylene, 1,3-dimethylbutylene, 2,3-dimethylbutylene, 2-ethylbutylene, n-heptylene, 2-methylhexylene, 3-methylhexylene, 2,2-dimethylpentylene, 3,3-dimethylpentylene, 2,3-dimethylpentylene, 2,4-dimethylpentylene, 3-ethylpentylene, or 2,2,3-trimethylbutylene;

[0025] The "cycloalkyl" is C3-C 10 Monocyclic or bicyclic cycloalkyl, optionally, C3-C7 monocyclic cycloalkyl; optionally, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl;

[0026] The "heterocyclic group" is a 3-10-membered non-aromatic heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O and S on the ring; alternatively, the heterocyclic group is a 3-10-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and O on the ring; alternatively, the heterocyclic group is a 3-6-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and O on the ring; alternatively, the heterocyclic group is a 3-10-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and S on the ring; alternatively, the heterocyclic group is a 3-6-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and S on the ring;

[0027] The "aryl" is a 6-10 membered aryl; optionally, it is phenyl or naphthyl; optionally, it is phenyl, 1-naphthyl, or 2-naphthyl;

[0028] The "arylene group" is a 6-10 membered arylene group; optionally, it is a phenylene group or a naphthylene group;

[0029] The "heteroaryl" is a 5-10 membered heteroaromatic ring group containing 1-3 heteroatoms selected from N, O and S on the ring; alternatively, it is a 5-10 membered heteroaromatic ring group containing 1-2 heteroatoms selected from N, O and S on the ring; alternatively, the heteroaromatic ring group is selected from a pyridine ring group, a pyrrole ring group, a pyrimidine ring group, a pyrazine ring group, a pyridazine ring group, a thiophene ring group, or a furan ring group; alternatively, the heteroaromatic group is selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazine-3-yl, pyridazine-4-yl, pyrimidine-2-yl, pyrimidine-4-yl, pyrimidine-5-yl, pyrazine yl, pyrazin-3-yl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, quinolizinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, naphthyridinyl, quinazolinyl, quinoxalinyl, thieno[2,3-b]furanyl, furano[3,2-b]pyranyl, pyrido[2,3-d]oxazinyl, pyrazolo[4,3-d]oxazolyl, imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl, benzothiophenyl, benzoxazolyl, benzimidazo[2,3-d]oxazinyl, oxazolyl, benzothiazolyl, benzoxazolinyl, benzoxazinyl, benzofuranyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-d]pyridinyl, pyrazolo[3,4-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazolo[2,3-b]pyrazinyl, or pyrimido[4,5-d]pyrimidinyl; optionally, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl;

[0030] The "heteroaryl group" is a 5-10 membered heteroaromatic ring group containing 1-3 heteroatoms selected from N, O and S on the ring; alternatively, it is a 5-10 membered heteroaromatic ring group containing 1-2 heteroatoms selected from N, O and S on the ring; alternatively, the heteroaromatic ring group is selected from a pyridine ring group, a pyrrole ring group, a pyrazole ring group, a pyrimidine ring group, a pyrazine ring group, a pyridazine ring group, a thiophene ring group, or a furan ring group.

[0031] According to the tricyclic pyrimidone compound represented by formula (I) or a pharmaceutically acceptable salt thereof provided by the present invention, optionally,

[0032] n1, n2, n3 are each independently 1 or 2; optionally, n1 is 1, optionally, n2 is 1 or 2, optionally, n3 is 1;

[0033] R1 and R2 are each independently selected from: -H, or C 1-7 Straight or branched alkyl; optionally, -H, or C 1-4 Straight or branched alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, or sec-butyl); Optionally, R1 is -H or -CH3; Optionally, R2 is -H or -CH3;

[0034] X1 and X2 are each independently selected from: C1-C7 alkylene (optionally, -CH2-, ethylene, n-propylene, isopropylene, n-butylene, or isobutylene), -O-, -S-, or -NR′-; optionally, X1 is -CH2-, or -O-; optionally, X1 is -O-; optionally, X2 is -O-; wherein R′ is selected from -H, C1-C7 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl , 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl), deuterated alkyl (optionally, -CD3, -C2D5, or -C3D7), or C3-C6 cycloalkyl (e.g., cyclopropane, cyclobutane, cyclopentane, or cyclohexane);

[0035] Ar is phenylene or pyridyl, the phenylene or pyridyl is optionally substituted by 0, 1, 2 or 3 substituents, each of which is independently selected from: -F, -Cl, -Br, -I, -CN, -Me, -CF3, -C2H5, -C3H7, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CD3, -OCD3, -OMe, or -OCF3; alternatively, Ar is phenylene, the phenylene is optionally substituted by 1 or 2 substituents, the substituents are -F, or -CN;

[0036] Y is -H, halogen, methyl, ethyl, n-propyl, isopropyl, -CD3, -OCD3, -CF3, -CHF2, -CH2F, -CH2CF3, -OCF3, -OCHF2, -OCH2F, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -OCH3, -OC2H5, -OC3H7, or -OAr'; Alternatively, Y is -H, -F, -Cl, -Br, -I, or -OAr'; Alternatively, Y is -H, -F, or -OAr'; wherein Ar' is selected from 1, phenyl, pyridyl, pyrimidyl, thienyl, pyrrolyl, pyrazolyl, or quinolyl substituted with 2 or 3 substituents, each of which is independently selected from: -F, -Cl, -Br, -CN, C1-C7 alkyl (optionally methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethyl butyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl), -CD3, -OCD3, C1-C6 haloalkyl, -OCH3, -OC2H7, -OC3H7, C1- C6 haloalkoxy, halosulfanyl (optionally, fluorosulfanyl or chlorosulfanyl), hydroxyl, hydroxyalkyl, cyano, or C3-C6 cycloalkyl (optionally cyclopropanyl, cyclobutanyl, cyclopentanyl, or cyclohexanyl); optionally, Ar′ is selected from phenyl, pyridin-3-yl, pyridin-4-yl, pyrazol-4-yl, quinolin-7-yl, or pyrimidin-5-yl, optionally substituted with 1 or 2 substituents selected from -F, -Cl, -CH3, -CF3, -CH2CF3, -OCF3, or -SF5;

[0037] Z is O.

[0038] According to the tricyclic pyrimidone compound represented by formula (I) or a pharmaceutically acceptable salt thereof provided by the present invention, optionally,

[0039] n1 is 1, n2 is 1 or 2, and n3 is 1;

[0040] R1 and R2 are each independently -H or methyl;

[0041] X1 is -O- or -CH2-, and X2 is -O-;

[0042] Ar is a phenylene group, and the phenylene group is optionally substituted by 1 or 2 substituents, and the substituents are -F or -CN;

[0043] Y is -H, -F, or -OAr'; wherein Ar' is phenyl, pyridin-3-yl, pyridin-4-yl, pyrazol-4-yl, quinolin-7-yl, or pyrimidin-5-yl, which is optionally substituted with 1 or 2 substituents selected from -Cl, -CH3, -CF3, -CH2CF3, -OCF3, or -SF5;

[0044] Z is O.

[0045] According to the tricyclic pyrimidone compound of formula (I) or a pharmaceutically acceptable salt thereof provided by the present invention, optionally, the compound of formula (I) is selected from the following compounds:

[0046]

[0047] According to the tricyclic pyrimidone compound of formula (I) or a pharmaceutically acceptable salt thereof provided by the present invention, wherein the pharmaceutically acceptable salt comprises an anionic salt or a cationic salt of the compound of formula (I);

[0048] Optionally, the pharmaceutically acceptable salt includes an alkali metal salt, an alkaline earth metal salt, or an ammonium salt of the compound of formula (I); optionally, the alkali metal includes sodium, potassium, lithium, or cesium, and the alkaline earth metal includes magnesium, calcium, or strontium;

[0049] Optionally, the pharmaceutically acceptable salt includes a salt formed by a compound of formula (I) and an organic base; Optionally, the organic base includes trialkylamine, pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-alkylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene, or 1,4-diazabicyclo[2.2.2]octane; Optionally, the trialkylamine includes trimethylamine, triethylamine, or N-ethyldiisopropylamine; Optionally, the N-alkylmorpholine includes N-methylmorpholine;

[0050] Optionally, the pharmaceutically acceptable salt includes a salt formed by a compound of formula (I) and an acid; optionally, the acid includes an inorganic acid or an organic acid; optionally, the inorganic acid includes hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, or carbonic acid; optionally, the organic acid includes formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, glutamic acid, or pamoic acid.

[0051] On the other hand, the present invention also provides a pharmaceutical composition comprising one or more of the compounds of formula (I) or pharmaceutically acceptable salts thereof and optionally a pharmaceutically acceptable carrier.

[0052] According to the pharmaceutical composition provided by the present invention, optionally, the dosage form of the pharmaceutical composition includes an oral preparation, a rectal preparation, or a parenteral preparation;

[0053] Optionally, the oral preparation includes a solid preparation or a liquid preparation; Optionally, the solid preparation includes a tablet, a powder, a granule, or a capsule; Optionally, the liquid preparation includes an aqueous or oil suspension, or a syrup;

[0054] Optionally, the preparation for parenteral administration includes a solution for injection, or an aqueous or oily suspension.

[0055] On the other hand, the present invention also provides use of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the present invention in the preparation of an Lp-PLA2 inhibitor.

[0056] On the other hand, the present invention also provides the use of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the present invention in the preparation of a drug for treating neurodegenerative diseases, cardiovascular diseases, diabetic macular edema (DME) or prostate diseases;

[0057] Optionally, the neurodegeneration-related disease includes Alzheimer's disease (AD), glaucoma, or age-related macular degeneration (AMD); and the cardiovascular disease includes atherosclerosis.

[0058] On the other hand, the present invention also provides a method for preparing the compound of formula (I) or a pharmaceutically acceptable salt thereof according to the present invention, the method comprising the following preparation route 1 or route 2:

[0059] Route 1:

[0060]

[0061] In each structural formula, n1, n2, n3, R1, R2, X1, X2, Z, Ar and Y are as defined above. Pg is a protecting group; optionally, Pg is tert-butyldiphenylsilyl.

[0062] In route 1, compound 1A and compound 1B are subjected to aromatic nucleophilic substitution to generate compound 1C; compound 1C is condensed with aldehyde to generate compound 1D; compound 1D is deprotected and methylated to generate compound 1E, compound 1E is intramolecularly cyclized to generate compound 1F (Z=O), compound 1F is sulfided to generate compound 1G (Z=S), and compound 1F / 1G is coupled via CX to obtain compound 1H.

[0063] Route 2:

[0064]

[0065] In each structural formula, n1, n2, n3, R1, R2, X1, X2, Z, Ar and Y are defined as above. Pg is a protecting group; optionally, Pg is tert-butyldiphenylsilyl; J is a halogen atom; optionally, J is Cl, Br, or I.

[0066] In route 2, compound 2A is hydrogenated in the presence of a catalyst (e.g., Pd / C, or PtO2) to obtain compound 2B, compound 2B is nucleophilically substituted to obtain compound 2C, compound 2C is deprotected and mesylated to obtain compound 2D, compound 2D is intramolecularly cyclized to obtain compound 2E (Z=O), compound 2E is sulfided to obtain compound 2F (Z=S), and compound 2E / 2F is CX coupled to obtain compound 2G.

[0067] Herein, the compound of formula (I) or a pharmaceutically acceptable salt thereof of the present invention includes tautomers, mesomers, racemates, enantiomers, diastereomers, or mixtures thereof of the compound of formula (I).

[0068] The compound of formula (I) or a pharmaceutically acceptable salt thereof provided by the present invention is a tricyclic pyrimidone compound, which is a new Lp-PLA2 inhibitor, and can be used to treat neurodegenerative diseases such as Alzheimer's disease (AD), glaucoma and age-related macular degeneration (AMD), including cardiovascular diseases such as atherosclerosis, diabetic macular edema (DME), or prostate diseases. DETAILED DESCRIPTION

[0069] The present invention is further described by the following examples. It should be understood that the examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.

[0070] Example

[0071] The starting materials of the present invention can be synthesized according to methods known in the art, or purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, Accela ChemBio Inc, Darui Chemicals and other companies.

[0072] In the examples, unless otherwise specified, the solution refers to an aqueous solution.

[0073] In the examples, unless otherwise specified, the reaction temperature is room temperature, for example, 20-30°C.

[0074] Embodiment 1:

[0075] Compound 1: 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0076]

[0077] Synthesis of 3-((tert-butyldiphenylsilyl)oxy)propan-1-amine 1c:

[0078]

[0079] Compound 3-aminopropan-1-ol 1ca (20.0 g, 266.25 mmol) was dissolved in dichloromethane (200 mL), imidazole (27.2 g, 399.41 mmol) was added, the temperature was lowered to 0°C, tert-butyldiphenylsilyl chloride (TBDPSCl) (87.9 g, 319.53 mmol) was slowly added, the temperature was slowly raised to room temperature and stirred for 16 h. Water (200 mL) was added to the reaction solution, and dichloromethane (100 mL*1) was used for extraction, dried over anhydrous sodium sulfate, concentrated, and column chromatography (ethyl acetate: petroleum ether = 1:1) was performed to obtain yellow oily liquid compound 1c (30.0 g, 36%).

[0080] LC-MS: [M+H] + :314.2

[0081] Synthesis of (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 1i:

[0082]

[0083] Compound 3,4,5-trifluorobenzaldehyde 1ia (23.0 g, 143.67 mmol), 2-(trifluoromethyl)pyridin-4-ol 1ib (25.8 g, 158.04 mmol), potassium carbonate (19.9 g, 143.67 mmol) were dissolved in DMF (200 mL) and reacted at 90°C for 1 h. After cooling to room temperature, the reaction solution was poured into ice water (2 L), extracted with ethyl acetate (500 mL*3), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by chromatography column (ethyl acetate: petroleum ether = 1:5) to obtain white solid compound 1ic (22.0 g, 51%).

[0084] LC-MS: [M+H] + :304.0.

[0085] Compound 3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde 1ic (20.0 g, 65.97 mmol) was dissolved in ethanol (200 mL), cooled to 0°C, sodium borohydride (2.5 g, 65.97 mmol) was added, and the temperature was slowly raised to room temperature and stirred for 1 h. The reaction solution was spin-dried, added to water (500 mL), extracted with ethyl acetate (300 mL*3), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by chromatography column (ethyl acetate: petroleum ether = 1:1) to obtain white solid compound 1i (20.0 g, 99%).

[0086] LC-MS: [M+H] + :306.1.

[0087] Synthesis of (2,4,6-trichloropyrimidin-5-yl)methanol 1b:

[0088]

[0089] Compound 2,4,6-trichloropyrimidine-5-carboxaldehyde 1a (25.0 g, 118.24 mmol) was dissolved in tetrahydrofuran (250 mL), cooled to 0°C, sodium borohydride (6.7 g, 177.36 mmol) was added, and the temperature was slowly raised to room temperature and stirred for 1 h. Water (100 mL) was added dropwise to quench, and ethyl acetate (300 mL*2) was used for extraction, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (ethyl acetate: petroleum ether = 1:2) to obtain white solid compound 1b (15.0 g, 59%).

[0090] LC-MS: [M+H] + :213.0.

[0091] Synthesis of (4-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-2,6-dichloropyrimidin-5-yl)methanol 1d:

[0092]

[0093] Compound (2,4,6-trichloropyrimidin-5-yl)methanol 1b (10.0 g, 46.85 mmol), 3-((tert-butyldiphenylsilyl)oxy)propan-1-amine 1c (13.2 g, 42.17 mmol), N,N-diisopropylethylamine (9.1 g, 70.28 mmol) were dissolved in acetonitrile (200 mL) and stirred at room temperature for 2 h. The reaction solution was dried and purified by column chromatography (ethyl acetate: petroleum ether = 1:10) to obtain a white solid compound 1d (15.0 g, 65%).

[0094] LC-MS: [M+H] + :490.4.

[0095] Synthesis of 1-(3-((tert-butyldiphenylsilyl)oxy)propyl)-5,7-dichloro-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazine 1e:

[0096]

[0097] Compound (4-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-2,6-dichloropyrimidin-5-yl)methanol 1d (2.0 g, 4.08 mmol) and p-toluenesulfonic acid (1.4 g, 8.15 mmol) were dissolved in toluene (30 mL), and formaldehyde (37% in H2O, 661.6 mg, 8.16 mmol) was added, and the temperature was raised to 100°C and stirred for 16 h. Saturated sodium carbonate (200 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (100 mL*2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (ethyl acetate: petroleum ether = 1:20) to obtain white solid compound 1e (1.2 g, 59%).

[0098] LC-MS: [M+H] + :502.0.

[0099] Synthesis of 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)yl)propan-1-ol 1f:

[0100]

[0101] Compound 1-(3-((tert-butyldiphenylsilyl)oxy)propyl)-5,7-dichloro-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazine 1e (1.2 g, 2.39 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0°C, and tetrabutylammonium fluoride (1M in THF, 4.8 mL, 4.80 mmol) was slowly added, and the temperature was slowly raised to room temperature and stirred for 2 h. Water (20 mL) was slowly added to quench, and the mixture was extracted with ethyl acetate (40 mL*2), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (ethyl acetate: petroleum ether = 1:2) to obtain white solid compound 1f (500.0 mg, 79%).

[0102] LC-MS: [M+H] + :264.0.

[0103] Synthesis of 1 g of 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazine-1(4H)-yl)propyl methanesulfonate:

[0104]

[0105] Compound 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)yl)propan-1-ol 1f (500.0 mg, 1.89 mmol) and triethylamine (287.4 mg, 2.84 mmol) were dissolved in dichloromethane (10 mL), cooled to 0°C, methylsulfonyl chloride (260.2 mg, 2.27 mmol) was added, and the mixture was heated to room temperature and stirred for 1 h. The reaction solution was spin-dried to obtain 1 g (800.0 mg crude) of the crude compound.

[0106] LC-MS: [M+H] + :342.0.

[0107] Synthesis of 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthran-7-one 1h:

[0108]

[0109] Dissolve 1g (800.0mg, crude) of the compound 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)propyl methanesulfonate and potassium carbonate (783.7mg, 5.67mmol) in dioxane (10mL) and water (10mL), and heat to 90℃ and stir for 2h. Cool down and filter, spin dry the reaction solution, add methanol (10mL) and dichloromethane (100mL) and stir for 0.5h, then filter, spin dry the filtrate to obtain 1h (90.0mg, 17%). LC-MS: [M+H]+ :228.0.

[0110] Compound 1: Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0111]

[0112] Compound 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (100.0 mg, 0.44 mmol), (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 1i (134.1 mg, 0.44 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium (Xantphos Pd G3) (41.6 mg, 0.04 mmol), and cesium carbonate (214.8 mg, 0.66 mmol) were dissolved in dioxane (10 mL), the temperature was raised to 100° C. and stirred for 2 h. The reaction mixture was cooled and filtered, water (100 mL) was added to the reaction solution, extracted with ethyl acetate (30 mL*2), dried over anhydrous sodium sulfate, filtered, concentrated, and prepared for separation (formic acid system) to obtain compound 1 (35.6 mg, 16%) as a white solid.

[0113] LC-MS: [M+H] + :497.0.

[0114] 1 H NMR(400MHz, CDCl3)δ8.60(d,J=6.0Hz,1H),7.27(s,1H),7.12-7.07(m,2H),6.98(dd,J=5.6,2.4,1H), 5.43(s,2H),4.78(s,2H),4.69(s,2H),3.99(t,J=5.6Hz,2H),3.33(t,J=5.6Hz,2H),2.18-2.12(m,2H).

[0115] Embodiment 2:

[0116] Compound 2: 6-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-2,3,7,8-tetrahydro-1H,4H,10H-9-oxa-3a,5,10-triazacyclohepta[de]naphthalen-4-one

[0117]

[0118] Synthesis of ethyl 2-(2,4,6-trihydroxypyrimidin-5-yl)acetate 2b:

[0119]

[0120] Compound 1,1,2-tricarboxylic acid triethyl ester 2a (100.0 g, 406.07 mmol), urea (24.4 g, 406.07 mmol) and sodium ethoxide (41.4 g, 609.11 mmol) were dissolved in ethanol (500 mL), replaced with nitrogen three times, heated to 80 ° C and stirred for 18 hours. The reaction solution was concentrated, diluted with water (500 mL), adjusted to pH = 2-3 with dilute hydrochloric acid solution (1M), and the solvent was concentrated under reduced pressure. It was extracted with ethyl acetate (500 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a white solid product compound 2b (11.8 g, 14%).

[0121] LC-MS: [M+H] + :215.0.

[0122] Synthesis of ethyl 2-(2,4,6-trichloropyrimidin-5-yl)acetate 2c:

[0123]

[0124] 2-(2,4,6-trihydroxypyrimidin-5-yl)acetic acid ethyl ester 2b (11.8 g, 55.09 mmol) and N,N-diisopropylethylamine (17.2 g, 133.11 mmol) were dissolved in phosphorus oxychloride (110 mL), replaced with nitrogen three times, heated to 100°C and stirred for 2 h. The reaction solution was concentrated to dryness, ice water (100 mL) was added to the residue at 0°C, saturated sodium bicarbonate solution was added, the pH was adjusted to 7-8, and extracted with ethyl acetate (200 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 7:1) to obtain a colorless oil product compound 2c (8.0 g, 54%).

[0125] LC-MS: [M+H] + :269.2,271.2.

[0126] Synthesis of 2-(2,4,6-trichloropyrimidin-5-yl)ethane-1-ol 2d:

[0127]

[0128] Compound 2-(2,4,6-trichloropyrimidin-5-yl)ethyl acetate 2c (8.0 g, 29.68 mmol) was dissolved in tetrahydrofuran (200 mL), cooled to 0°C, and diisobutylaluminum hydride (59.4 mL, 89.04 mmol, 1.5 M in hexane) was added dropwise, and the mixture was returned to room temperature and stirred for 3 h. The mixture was cooled to 0°C, and a saturated aqueous ammonium chloride solution (100 mL) was added dropwise to quench the reaction, and the mixture was extracted with ethyl acetate (100 mL x 3), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a colorless oil product compound 2d (4.0 g, 59%).

[0129] LC-MS: [M+H] + :227.2,229.2.

[0130] Synthesis of 2-(4-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-2,6-dichloropyrimidin-5-yl)ethan-1-ol 2e:

[0131]

[0132] Compound 2-(2,4,6-trichloropyrimidin-5-yl)ethane-1-ol 2d (4.0 g, 17.58 mmol) and N,N-diisopropylethylamine (3.4 g, 26.38 mmol) were dissolved in acetonitrile (60 mL), and 3-((tert-butyldiphenylsilyl)oxy)propan-1-amine 1c (8.3 g, 26.38 mmol) was added at 0°C, and nitrogen was replaced three times. The reaction was stirred at 0°C for 3 minutes, and then returned to room temperature and stirred for 2 hours. The reaction solution was concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a colorless oil compound 2e (6.9 g, 78%). LC-MS: [M+H] + :504.2.

[0133] Synthesis of 1-(3-((tert-butyldiphenylsilyl)oxy)propyl)-6,8-dichloro-1,2,4,5-tetrahydropyrimido[4,5-d][1,3]oxazepane 2f:

[0134]

[0135] Compound 2-(4-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-2,6-dichloropyrimidin-5-yl)ethane-1-ol 2e (6.7 g, 13.28 mmol), p-toluenesulfonic acid (3.4 g, 19.92 mmol) and formaldehyde (14.4 mL, 199.2 mmol, 37% in H2O) were dissolved in toluene (100 mL), replaced with nitrogen three times, and heated to 100°C for stirring and reaction for 16 h. Saturated sodium carbonate (100 mL) was added to the reaction solution, and extracted with ethyl acetate (100 mL x 2). The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:5) and dried to obtain white solid compound 2f (3.1 g, 45%).

[0136] LC-MS: [M+H] + :516.2.

[0137] Synthesis of 2g of 3-(6,8-dichloro-4,5-dihydropyrimido[4,5-d][1,3]oxazepan-1(2H)-yl)propan-1-ol:

[0138]

[0139] The compound 1-(3-((tert-butyldiphenylsilyl)oxy)propyl)-6,8-dichloro-1,2,4,5-tetrahydropyrimido[4,5-d][1,3]oxazepane 2f (3.1 g, 6.00 mmol) was dissolved in tetrahydrofuran (50 mL), cooled to 0°C, tetrabutylammonium fluoride (12.0 mL, 12.00 mmol, 1.0 M in THF) was added dropwise, and the mixture was returned to room temperature and stirred for 2 h. Water (20 mL) was slowly added, and the mixture was extracted with dichloromethane (20 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 3:2) to obtain a white solid product compound 2g (1.5 g, 90%).

[0140] LC-MS: [M+H] + :278.0.

[0141] Synthesis of 3-(6,8-dichloro-4,5-dihydropyrimido[4,5-d][1,3]oxazepan-1(2H)-yl)propyl methanesulfonate 2h:

[0142]

[0143] Dissolve 2g (1.5g, 5.39mmol) of 3-(6,8-dichloro-4,5-dihydropyrimido[4,5-d][1,3]oxazepan-1(2H)-yl)propan-1-ol and triethylamine (1.6g, 16.17mmol) in dichloromethane (20mL), cool to 0°C, add methylsulfonyl chloride (741.1mg, 6.47mmol), return to room temperature, stir and react for 1h. The reaction solution was spin-dried to obtain crude compound 2h (1.9g, crude).

[0144] LC-MS: [M+H] + :356.0.

[0145] Synthesis of 6-chloro-2,3,7,8-tetrahydro-1H,4H,10H-9-oxa-3a,5,10-triazacyclohepta[de]naphthalen-4-one 2i:

[0146]

[0147] 3-(6,8-dichloro-4,5-dihydropyrimido[4,5-d][1,3]oxazepan-1(2H)-yl)propyl methanesulfonate 2h (1.9 g, crude) and potassium carbonate (2.2 g, 16.17 mmol) were dissolved in water (10 mL) and dioxane (10 mL), replaced with nitrogen three times, heated to 90°C, and stirred for 2 h. The reaction solution was cooled and filtered, and the reaction solution was spin-dried, methanol (10 mL) and dichloromethane (100 mL) were added and stirred for 0.5 hours, then filtered, and the filtrate was concentrated. The residue was purified by column chromatography (dichloromethane: methanol = 10:1) to obtain a white solid product compound 2i (220 mg, 17%, two-step yield).

[0148] LC-MS: [M+H] + :242.0.

[0149] Compound 2: Synthesis of 6-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-2,3,7,8-tetrahydro-1H,4H,10H-9-oxa-3a,5,10-triazacyclohepta[de]naphthalen-4-one:

[0150]

[0151] 6-Chloro-2,3,7,8-tetrahydro-1H,4H,10H-9-oxa-3a,5,10-triazacyclohepta[de]naphthalen-4-one 2i (100.0 mg, 0.41 mmol), (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 1i (125.1 mg, 0.41 mmol), cesium carbonate (267.2 mg, 0.82 mmol) and methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)) (38.0 mg, 0.04 mmol) were dissolved in dioxane (10 mL), replaced with nitrogen three times, and heated to 100 ° C and stirred for 2 h. The reaction mixture was cooled and filtered, and water (10 mL) and ethyl acetate (20 mL x 2) were added to extract the mixture, which was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (dichloromethane: methanol = 10:1) to obtain white solid compound 2 (21.8 mg, 10%).

[0152] LC-MS: [M+H] + :511.2.

[0153] 1 H NMR (400MHz, CDCl3) δ8.60(d,J=5.6Hz,1H),7.26(s,1H),7.12(d,J=8.4Hz,2H),6.99(dd,J=5.6,2.0Hz,1H),5.42(s,2H), 4.95(s,2H),4.11(t,J=5.2Hz,2H),4.02(t,J=5.6Hz,2H),3.50(t,J=6.4Hz,2H),2.93(t,J=5.2Hz,2H),2.14-2.08(m,2H).

[0154] Embodiment 3:

[0155] Compound 3: 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-2,3,5,6-tetrahydro-1H-3a,6a,8-triazaphenanthran-7(4H)-one

[0156]

[0157] Synthesis of 2,4-dichloro-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine 3b:

[0158]

[0159] Compound 2,4-dichloropyrido[2,3-d]pyrimidine 3a (7.0 g, 34.40 mmol) was dissolved in ethanol (100 mL), and platinum dioxide (0.7 g, 3.08 mmol) was added. The hydrogen gas was replaced three times, and the reaction was stirred at room temperature for 4 hours. The reaction solution was filtered and concentrated, and the residue was purified by column (petroleum ether: ethyl acetate = 10:1) to obtain yellow oil compound 3b (1.3 g, 18%).

[0160] LC-MS: [M+H] + :204.4.

[0161] Synthesis of 8-(3-((tert-butyldimethylsilyl)oxy)propyl)-2,4-dichloro-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine 3c:

[0162]

[0163] Compound 2,4-dichloro-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine 3b (1.3 g, 6.37 mmol), (3-bromopropoxy)(tert-butyl)dimethylsilane (1.9 g, 7.65 mmol) and cesium carbonate (2.4 g, 7.35 mmol) were dissolved in DMSO (20 mL), replaced with nitrogen three times, and heated to 80 ° C with stirring for 2 h. The reaction solution was filtered, the filtrate was purified by reverse phase, concentrated and freeze-dried to obtain a yellow oil compound 3c (1.1 g, 46%). LC-MS: [M+H] + :376.2.

[0164] Synthesis of 3-(2,4-dichloro-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)propan-1-ol 3d:

[0165]

[0166] Compound 8-(3-((tert-butyldimethylsilyl)oxy)propyl)-2,4-dichloro-5,6,7,8-tetrahydropyridine[2,3-d]pyrimidine 3c (1.1 g, 2.92 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0°C, tetrabutylammonium fluoride (5.8 mL, 5.84 mmol, 1 M in THF) was added dropwise, returned to room temperature, and stirred for 2 h. Water (20 mL) was added to the reaction solution, and the tetrahydrofuran was removed by concentration under reduced pressure. Dichloromethane (30 mL x 3) was added for extraction, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by column (petroleum ether: ethyl acetate = 1:1) to obtain a white oil compound 3d (360 mg, 47%).

[0167] LC-MS: [M+H]+ :262.0.

[0168] Synthesis of 3-(2,4-dichloro-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)propyl methanesulfonate 3e:

[0169]

[0170] Compound 3-(2,4-dichloro-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)propan-1-ol 3d (360 mg, 1.37 mmol) and triethylamine (277.3 mg, 2.74 mmol) were dissolved in dichloromethane (10 mL), cooled to 0°C, methylsulfonyl chloride (188.8 mg, 1.65 mmol) was added dropwise, returned to room temperature, stirred and reacted for 2 h. The reaction solution was concentrated to obtain a crude compound 3e (530 mg, crude product).

[0171] LC-MS: [M+H] + :340.0.

[0172] Synthesis of 9-chloro-2,3,5,6-tetrahydro-1H-3a,6a,8-triazaphenanthran-7(4H)-one 3f:

[0173]

[0174] Compound 3-(2,4-dichloro-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)propyl methanesulfonate 3e (530 mg, 1.37 mmol, crude product) and potassium carbonate (568.0 mg, 4.11 mmol) were dissolved in dioxane (10 mL) and water (10 mL). The mixture was replaced with nitrogen three times, heated to 90°C, and stirred for 2 h. The solvent was concentrated to dryness, extracted with dichloromethane (10 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by column (dichloromethane: methanol = 10:1) to obtain a white solid compound 3f (150 mg, 48%, two-step yield).

[0175] LC-MS: [M+H] + :226.0.

[0176] Compound 3: Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-2,3,5,6-tetrahydro-1H-3a,6a,8-triazaphenanthran-7(4H)-one:

[0177]

[0178] Compound 9-chloro-2,3,5,6-tetrahydro-1H-3a,6a,8-triazaphenanthren-7(4H)-one 3f (50 mg, 0.22 mmol), (3,5-difluoro-4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)methanol 1i (74.4 mg, 0.24 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (21.0 mg, 0.02 mmol) and cesium carbonate (144.4 mg, 0.44 mmol) were dissolved in dioxane (5 mL), replaced with nitrogen three times, heated to 100 ° C, and stirred for 2 h. The reaction solution was filtered, and the filtrate was concentrated to dryness under reduced pressure. The crude product was freeze-dried by reverse phase preparation (formic acid system) to obtain compound 3 (22.4 mg, 20%) as a white solid.

[0179] LC-MS: [M+H] + :495.4.

[0180] 1 H NMR (400MHz, CDCl3) δ8.59(d,J=5.6Hz,1H),7.27(s,1H),7.11(d,J=8.0Hz,2H),6.98(dd,J=5.6,2.4Hz,1H),5.4 2(s,2H),3.99(t,J=6.0Hz,2H),3.37-3.31(m,4H),2.56(t,J=6.4Hz,2H),2.12-2.06(m,2H),1.96-1.90(m,2H).

[0181] Embodiment 4:

[0182] Compound 4 and Compound 5: (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one and (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0183]

[0184] Synthesis of 4-((tert-butyldiphenylsilyl)oxy)butan-2-amine 4b:

[0185]

[0186] 3-Aminobutan-1-ol 4a (10.0 g, 112.18 mmol) and imidazole (11.5 g, 168.27 mmol) were dissolved in dichloromethane (200 mL), tert-butyldiphenylsilyl chloride (37.0 g, 134.62 mmol) was slowly added, and the mixture was stirred at room temperature for 24 h. 100 mL of water was added to the reaction solution, extracted with dichloromethane (200 mL x 2), washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 7:1) to obtain a colorless oil compound 4b (21.5 g, 59%).

[0187] LC-MS: [M+H] + :328.4.

[0188] Synthesis of (4-((4-(tert-butyldiphenylsilyl)oxy)butan-2-yl)amino)-2,6-dichloropyrimidin-5-yl)methanol 4c:

[0189]

[0190] 4-((tert-butyldiphenylsilyl)oxy)butan-2-amine 4b (15.0 g, 45.80 mmol), (2,4,6-trichloropyrimidin-5-yl)methanol (9.8 g, 45.80 mmol), N,N-diisopropylethylamine (8.9 g, 68.70 mmol) were dissolved in acetonitrile (200 mL) and stirred at room temperature for 24 h. The mixture was concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 8:1) to obtain a light yellow solid product compound 4c (13.0 g, 56%).

[0191] LC-MS: [M+H] + :504.2.

[0192] Synthesis of 1-(4-((tert-butyldiphenylsilyl)oxy)butan-2-yl)-5,7-dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazine 4d:

[0193]

[0194] (4-(4-((tert-butyldiphenylsilyl)oxy)butan-2-yl)amino)-2,6-dichloropyrimidin-5-yl)methanol 4c (12.0 g, 23.79 mmol), p-toluenesulfonic acid (6.1 g, 35.69 mmol), and formaldehyde aqueous solution (7.7 g, 95.16 mmol, 37% in H2O) were dissolved in toluene (150 mL), heated to 110°C, and stirred for 4 hours. The solvent was concentrated under reduced pressure, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain a light yellow solid product compound 4d (3.0 g, 24%).

[0195] LC-MS: [M+H] + :516.4.

[0196] Synthesis of 3-(5,7-dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)butan-1-ol 4e:

[0197]

[0198] 1-(4-((tert-butyldiphenylsilyl)oxy)but-2-yl)-5,7-dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazine 4d (3.0 g, 5.81 mmol) was dissolved in tetrahydrofuran (30 mL), tetrabutylammonium fluoride (8.7 mL, 8.71 mmol, 1.0 M in THF) was added dropwise, and the mixture was stirred at room temperature for 2 h. The solvent was concentrated under reduced pressure, extracted with ethyl acetate (20 mL x 2), the organic phases were combined, washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a light yellow solid product compound 4e (780.0 mg, 48%).

[0199] LC-MS: [M+H] + :278.2.

[0200] Synthesis of butyl 3-(5,7-dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)methanesulfonate 4f:

[0201]

[0202] 3-(5,7-Dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)butan-1-ol 4e (780 mg, 2.80 mmol) and triethylamine (426.1 mg, 4.21 mmol) were dissolved in dichloromethane (15 mL), and methylsulfonyl chloride (386.0 mg, 3.37 mmol) was added dropwise, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated to dryness under reduced pressure to obtain compound 4f (1.06 g, crude product) as a yellow oil, which was used directly in the next step.

[0203] LC-MS: [M+H] + :356.0.

[0204] Synthesis of 4g of 9-chloro-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0205]

[0206] 3-(5,7-Dichloro-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)methanesulfonic acid butyl ester 4f (1.06 g, 2.80 mmol) and potassium carbonate (774.0 mg, 5.60 mmol) were dissolved in water (10 mL) and 1,4-dioxane (10 mL), and the reaction was stirred at 90°C for 2 h. The crude product was purified by column chromatography (dichloromethane: methanol = 15:1) to give a yellow solid compound 4g (200.0 mg, 30%, two-step yield).

[0207] LC-MS: [M+H] + :242.0.

[0208] Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenanthran-7(1H)-one 4h:

[0209]

[0210] 9-Chloro-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthren-7(1H)-one 4g (85.0 mg, 0.35 mmol), (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 1i (107.3 mg, 0.35 mmol), methanesulfonic acid (4,5-bis(diphenylphosphino-9,9-dimethylxanthene)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (38.0 mg, 0.04 mmol), and cesium carbonate (342.1 mg, 1.05 mmol) were dissolved in 1,4-dioxane (10 mL), replaced with nitrogen three times, and reacted at 100° C. with stirring for 2 h. The crude product was purified by reverse phase preparation to obtain white solid compound 4h (35.0 mg, 20%).

[0211] LC-MS: [M+H] + :511.2.

[0212] Compound 4 and Compound 5: Synthesis of (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one and (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0213]

[0214] 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-4-methyl-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenanthran-7(1H)-one 4h (35.0 mg, 0.07 mmol) was separated by SFC and freeze-dried to give white solid compound 4 (14.0 mg, 40%) and white solid compound 5 (12.0 mg, 34%).

[0215] Instrument:Waters Prep SFC 150Mgm

[0216] Column:Daicel ChiralPak IG,40mm ID×250mm,10μm

[0217] Mobile phase:A for CO2 and B for MeOH

[0218] Gradient: B 35%

[0219] Flow rate: 120mL / min

[0220] Column temperature:40℃

[0221] Wavelength:210 / 254nm

[0222] Compound 4

[0223] RT:2.43min.

[0224] LC-MS: [M+H] + :511.0.

[0225] 1 H NMR (400MHz, CDCl3) δ8.60(d,J=6.0Hz,1H),7.27(s,1H),7.12-7.07(m,2H),6.98(dd,J=5.6,2.4Hz,1H),5.43(s,2H),4.80(dd,J=22.8,8. 8Hz,2H),4.68(dd,J=19.2,13.2Hz,2H),4.43-4.38(m,1H),3.65-3.58(m,2H),2.16-2.09(m,1H),1.99-1.94(m,1H),1.31(d,J=6.4Hz,3H).

[0226] Compound 5

[0227] RT:3.00min.

[0228] LC-MS: [M+H] + :511.2.

[0229] 1 H NMR (400MHz, CDCl3) δ8.60(d,J=6.0Hz,1H),7.27(s,1H),7.12-7.07(m,2H),6.98(dd,J=5.6,2.0Hz,1H),5.43(s,2H),4.80(dd,J=22.8,8. 8Hz,2H),4.68(dd,J=19.2,13.2Hz,2H),4.43-4.37(m,1H),3.65-3.58(m,2H),2.16-2.08(m,1H),1.99-1.94(m,1H),1.31(d,J=6.4Hz,3H).

[0230] Embodiment 5:

[0231] Compound 6 and Compound 7: (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one and (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one

[0232]

[0233] Synthesis of 3-((tert-butyldiphenylsilyl)oxy)-2-methylpropan-1-amine 6b:

[0234]

[0235] 3-Amino-2-methylpropan-1-ol 6a (4.0 g, 44.87 mmol), tert-butyldiphenylsilyl chloride (14.8 g, 53.85 mmol), imidazole (4.6 g, 67.31 mmol) were dissolved in dichloromethane (60 mL), stirred at room temperature for 16 h, added with water (100 mL), extracted with dichloromethane (50 mL x 3), the organic phases were combined, washed with saturated brine (30 mL x 1), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain a colorless oil product compound 6b (10.0 g, 68%). LC-MS: [M+H] + :328.4.

[0236] Synthesis of (4-((3-((tert-butyldiphenylsilyl)oxy)-2-methylpropyl)amino)-2,6-dichloropyrimidin-5-yl)methanol 6c:

[0237]

[0238] 3-((tert-Butyldiphenylsilyl)oxy)-2-methylpropan-1-amine 6b (11.5 g, 35.11 mmol), (2,4,6-trichloropyrimidin-5-yl)methanol (7.5 g, 35.11 mmol), N,N-diisopropylethylamine (9.1 g, 70.22 mmol) were dissolved in acetonitrile (200 mL), and the mixture was stirred at room temperature for 3 h. The reaction solution was concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain white solid compound 6c (6.5 g, 37%).

[0239] LC-MS: [M+H] + :504.2.

[0240] Synthesis of 1-(3-((tert-butyldiphenylsilyl)oxy)-2-methylpropyl)-5,7-dichloro-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazine 6d:

[0241]

[0242] (4-((3-((tert-butyldiphenylsilyl)oxy)-2-methylpropyl)amino)-2,6-dichloropyrimidin-5-yl)methanol 6c (6.5 g, 12.88 mmol), formaldehyde (14.4 mL, 193.20 mmol, in H2O, 37%), p-toluenesulfonic acid (3.7 g, 19.33 mmol) were dissolved in toluene (100 mL), replaced with nitrogen three times, stirred at 110°C for 3 h, the reaction solution was concentrated, saturated sodium carbonate (100 mL) and ethyl acetate (100 mL x 3) were added, the organic phases were combined, washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain yellow oil compound 6d (4.0 g, 60%).

[0243] LC-MS: [M+H] + :516.2,518.0.

[0244] Synthesis of 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)-2-methylpropan-1-ol 6e:

[0245]

[0246] 1-(3-((tert-Butyldiphenylsilyl)oxy)-2-methylpropyl)-5,7-dichloro-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazine 6d (4.0 g, 7.74 mmol) was dissolved in tetrahydrofuran (50 mL), cooled to 0°C, and tetrabutylammonium fluoride (15.5 mL, 15.49 mmol, 1.0 M in THF) was added dropwise. The reaction was stirred at 0°C for 3 h. Water (50 mL) was slowly added to the reaction solution, and the reaction solution was extracted with dichloromethane (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to give a yellow oily compound 6e (1.5 g, 70%).

[0247] LC-MS: [M+H] + :278.4.

[0248] Synthesis of 3-(5,7-dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)-2-methylmethanesulfonate 6f:

[0249]

[0250] 3-(5,7-Dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)-2-methylpropan-1-ol 6e (1.5 g, 5.39 mmol) and triethylamine (544.4 mg, 5.39 mmol) were dissolved in tetrahydrofuran (30 mL). Methanesulfonyl chloride (0.6 g, 5.39 mmol) was added dropwise to the reaction solution at 0°C. The mixture was returned to room temperature and stirred for 2 h. The reaction solution was concentrated to obtain yellow oil compound 6f (1.9 g, crude product for next step).

[0251] LC-MS: [M+H] + :356.0.

[0252] Synthesis of 9-chloro-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthran-7-one 6g:

[0253]

[0254] 3-(5,7-Dichloro-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)-2-methylmethanesulfonic acid propyl ester 6f (1.9 g, 5.39 mmol) and potassium carbonate (1.1 g, 8.00 mmol) were dissolved in water (20 mL) and 1,4-dioxane (20 mL), stirred at 90°C for 2 h, the reaction solution was filtered and concentrated, and the residue was purified by column chromatography (dichloromethane: methanol = 10:1) to obtain a yellow solid compound 6g (300.0 mg, 23%, two-step yield). LC-MS: [M+H] + :242.0.

[0255] Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one 6h:

[0256]

[0257] 9-Chloro-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 6g (200.0mg, 0.83mmol), (3,5-difluoro-4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)methanol 1i (252.6mg, 0.83mmol), methanesulfonic acid (4,5-bis(diphenylphosphino)-9,9-dimethyloxanthene) )(2-amino-1,1'-biphenyl-2-yl)palladium(II) (78.6 mg, 0.08 mmol) and cesium carbonate (539.6 mg, 1.66 mmol) were dissolved in 1,4-dioxane (5 mL), replaced with nitrogen three times, stirred at 100°C for 2 h, the reaction solution was filtered and concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain a yellow solid compound 6h (70.0 mg, 17%).

[0258] LC-MS: [M+H] + :511.3.

[0259] Compound 6 and Compound 7: Synthesis of (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one and (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one:

[0260]

[0261] 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5-methyl-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7(1H)-one 6h (70.0 mg, 0.14 mmol) was separated by SFC and freeze-dried to give white solid compound 6 (10.1 mg, 14%) and white solid compound 7 (11.5 mg, 16%).

[0262] Instrument:Waters Prep SFC 150Mgm-02

[0263] Column:ChiralPak IH,250×40mm ID,10μm

[0264] Mobile phase: A for CO2 and B for MeOH

[0265] Gradient: B 30%

[0266] Flow rate: 120mL / min

[0267] Back pressure: 100bar

[0268] Column temperature: 40℃

[0269] Wavelength: 210nm / 254nm

[0270] Compound 6

[0271] RT: 1.99min.

[0272] LC-MS: [M+H] + : 511.4.

[0273] 1 1H NMR(400MHz, CDCl3) δ8.60(d, J=5.6Hz, 1H), 7.27(s, 1H), 7.09(d, J=8.0Hz, 2H), 6.98(dd, J=5.6, 2.0Hz, 1H), 5.42(s, 2H), 4.77(s, 2H), 4.69(s, 2H), 4.43 - 4.38(m, 1H), 3.30 - 3.25(m, 1H), 3.22 - 3.17(m, 1H), 3.00 - 2.97(m, 1H), 2.27 - 2.20(m, 1H), 1.13(d, J=6.8Hz, 3H).

[0274] Compound 7

[0275] RT: 2.79min.

[0276] LC-MS: [M+H] + : 511.4.

[0277] 1H NMR (400MHz, CDCl3) δ8.60(d,J=5.6Hz,1H),7.27(s,1H),7.09(d,J=8.0Hz,2H),6.98(dd,J=5.6,2.0Hz,1H),5.42(s,2H),4.77(s,2H ),4.69(s,2H),4.43-4.38(m,1H),3.30-3.25(m,1H),3.22-3.17(m,1H),3.00-2.97(m,1H),2.27-2.20(m,1H),1.13(d,J=6.8Hz,3H).

[0278] Embodiment 6:

[0279] Compound 8 and Compound 9: (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one and (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0280]

[0281] Synthesis of 8a of 1-(3-((tert-butyldiphenylsilyl)oxy)propyl)-5,7-dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazine:

[0282]

[0283] (4-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-2,6-dichloropyrimidin-5-yl)methanol 1d (5.0 g, 10.19 mmol) and p-toluenesulfonic acid (2.9 g, 15.29 mmol) were dissolved in toluene (50 mL), acetaldehyde (10.2 mL, 50.97 mmol, 40% in THF) was added, and the mixture was heated to 100°C for 2 h. The toluene was dried by spin drying, and water (100 mL) and ethyl acetate (100 mL) were added. The pH was adjusted to 7-8 with saturated aqueous sodium bicarbonate solution (100 mL), and the mixture was extracted with ethyl acetate (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 6:4) to obtain colorless oily liquid compound 8a (2.0 g, 38%).

[0284] LC-MS: [M+H] +:516.2.

[0285] Synthesis of 3-(5,7-dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)propan-1-ol 8b:

[0286]

[0287] 1-(3-((tert-Butyldiphenylsilyl)oxy)propyl)-5,7-dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazine 8a (2.1 g, 4.07 mmol) was dissolved in tetrahydrofuran (20 mL), and the temperature was cooled to 0°C. Tetrabutylammonium fluoride (8.1 mL, 8.13 mmol, 1M in THF) was added dropwise to the reaction solution. The reaction was stirred at room temperature for 3 h, and water (30 mL) was added. The solvent was dried by spin drying, and the aqueous phase was extracted with dichloromethane (50 mL x 2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 2:8) to obtain white solid compound 8b (700.0 mg, 62%).

[0288] LC-MS: [M+H] + :278.0.

[0289] Synthesis of 3-(5,7-dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)propyl methanesulfonate 8c:

[0290]

[0291] 3-(5,7-Dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)propan-1-ol 8b (700.0 mg, 2.52 mmol) and triethylamine (764.0 mg, 7.55 mmol) were dissolved in dichloromethane (10 mL). Methanesulfonyl chloride (345.9 mg, 3.02 mmol) was added dropwise to the reaction solution at 0°C. The reaction was stirred at room temperature for 2 h and concentrated under reduced pressure to obtain yellow oily liquid compound 8c (1.2 g, crude product).

[0292] LC-MS: [M+H] + :356.0.

[0293] Synthesis of 9-chloro-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one 8d:

[0294]

[0295] 3-(5,7-Dichloro-2-methyl-2,4-dihydro-1H-pyrimido[4,5-d][1,3]oxazin-1-yl)propyl methanesulfonate 8c (1.1 g, 2.52 mmol, crude product) and potassium carbonate (696.6 mg, 5.04 mmol) were dissolved in dioxane (8 mL) and water (2 mL), heated to 90°C and stirred for 2 h, the solvent was concentrated under reduced pressure, dichloromethane (18 mL) and methanol (2 mL) were added to the residue, stirred for 10 minutes, filtered, and the filtrate was purified by column chromatography (dichloromethane: methanol = 9:1) to obtain white solid compound 8d (200.0 mg, 33%, two-step yield). LC-MS: [M+H] + :242.0.

[0296] Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenanthran-7(1H)-one 8e:

[0297]

[0298] Compound 9-chloro-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthren-7(1H)-one 8d (79.2 mg, 0.33 mmol), (3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 1i (100.0 mg, 0.33 mmol) and cesium carbonate (213.5 mg, 0.66 mmol) were dissolved in dioxane. To the precipitate (5 mL), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (31.1 mg, 0.03 mmol) was added, and the atmosphere was replaced with nitrogen three times. The reaction mixture was heated to 100°C and stirred for 2 h. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative (formic acid system) to obtain white solid compound 8e (70.0 mg, 42%).

[0299] LC-MS: [M+H] + :511.2.

[0300] Compounds 8 and 9: Synthesis of (S)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one and (R)-9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0301]

[0302] 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-3-methyl-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenanthran-7(1H)-one 8e (70.0 mg, 0.14 mmol) was separated by SFC to give white solid compound 8 (15.6 mg, 45%) and white solid compound 9 (15.4 mg, 44%).

[0303] Equipment:Waters UPCC system equipped with a PDA detector

[0304] Column:Daicel_ChiralPAK-IG_100x3.0mm_3μm

[0305] Column temperature:35℃

[0306] Flow rate:2.0ml / min

[0307] Wavelength:210nm

[0308] Compound 8

[0309] RT:2.71min.

[0310] LC-MS: [M+H] + :511.2.

[0311] 1 H NMR (400MHz, CDCl3) δ8.60(d,J=5.6Hz,1H),7.27(s,1H),7.10(d,J=8.0Hz,2H),6.98(dd,J=5.6,2.4Hz,1H),5.42(s,2H),4.94-4.90(m,1H),4.6 8(dd,J=30.8,13.6Hz,2H),4.18-4.12(m,1H),3.83-3.76(m,1H),3.41-3 .34(m,1H),3.30-3.24(m,1H),2.16-2.07(m,2H),1.52(d,J=5.6Hz,3H).

[0312] Compound 9

[0313] RT:3.54min.

[0314] LC-MS: [M+H] + :511.2.

[0315] 1 H NMR (400 MHz, CDCl3) δ8.60 (d, J = 5.6 Hz, 1H), 7.27 (s, 1H), 7.10 (d, J = 8.0 Hz, 2H), 6.98 (dd, J = 5.6, 2.4 Hz, 1H), 5.42 (s, 2H), 4.94-4.90 (m, 1H), 4.68 (dd, J = 30.8, 13.6 Hz, 2H), 4.18-4.12 (m, 1H), 3.83-3.76 (m, 1H), 3.41-3.34 (m, 1H), 3.30-3.24 (m, 1H), 2.17-2.07 (m, 2H), 1.52 (d, J = 5.6 Hz, 3H). Example 7:

[0316] Compound 10: 9-((3-fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0317]

[0318] Synthesis of 3-fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde 10b:

[0319]

[0320] 3,4-difluorobenzaldehyde 10a (10.0 g, 70.37 mmol), 2-(trifluoromethyl)pyridin-4-ol (11.5 g, 70.37 mmol) and cesium carbonate (45.9 g, 140.75 mmol) were dissolved in N,N-dimethylformamide (100 mL), heated to 80°C, and stirred for 3 h. The reaction solution was cooled to room temperature, filtered, and the filtrate was added with water (100 mL), extracted with ethyl acetate (100 mL x 2), and the organic phases were combined and washed with water (50 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The yellow oil compound 10b (5.3 g, 26%) was purified by column chromatography (petroleum ether: ethyl acetate = 1:1).

[0321] LC-MS: [M+H] + :286.0.

[0322] Synthesis of (3-fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 10c:

[0323]

[0324] 3-Fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzaldehyde 10b (1.0 g, 3.51 mmol) was dissolved in methanol (10 mL), cooled to 0°C under nitrogen protection, sodium borohydride (199.0 mg, 5.26 mmol) was added in batches, and the reaction was stirred at room temperature for 3 h. Saturated aqueous ammonium chloride solution (10 mL) was added to the reaction solution, and the methanol was spin-dried. The solution was extracted with ethyl acetate (20 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain white solid compound 10c (600.0 mg, 60%).

[0325] LC-MS: [M+H] + :288.4.

[0326] Compound 10: Synthesis of 9-((3-fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0327]

[0328] 9-Chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthran-7-one 1h (50.0 mg, 0.22 mmol), (3-fluoro-4-((2-(trifluoromethyl)pyridin-4-yl)oxy)phenyl)methanol 10c (63.2 mg, 0.22 mmol) and cesium carbonate (143.4 mg, 0.44 mmol) were dissolved in dioxane. (5mL), add methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (19.0 mg, 0.02 mmol), replace with nitrogen 3 times, heat to 100°C, stir and react for 2h, cool to room temperature, filter, spin dry the filtrate, and purify by reverse phase preparation (formic acid system) to obtain white solid compound 10 (4.7 mg, 4%). LC-MS: [M+H] + :479.2.

[0329] 1H NMR (400MHz, CDCl3) δ8.57(d,J=5.6Hz,1H),7.30-7.27(m,1H),7.24-7.23(m,2H),7.18(t,J=8.0Hz,1H),6.95(dd,J=5 .6,2.4Hz,1H),5.43(s,2H),4.77(s,2H),4.68(s,2H),3.99(t,J=6.0Hz,2H),3.32(t,J=6.0Hz,2H),2.17-2.11(m,2H).

[0330] Embodiment 8:

[0331] Compound 11: 5-((7-oxo-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-9-yl)oxy)methyl)-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile

[0332]

[0333] Synthesis of 5-formyl-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile 11b:

[0334]

[0335] 2-Fluoro-5-formylbenzonitrile 11a (10.0 g, 67.06 mmol), 2-(trifluoromethyl)pyridin-4-ol (10.9 g, 67.06 mmol), cesium carbonate (32.8 g, 100.60 mmol) were dissolved in N,N-dimethylformamide (100 mL), stirred at 90°C for 2 h. The reaction solution was diluted with water (100 mL), extracted with ethyl acetate (100 mL x 3), the organic phases were combined, washed with saturated brine (50 mL x 1), dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain white solid compound 11b (10.0 g, 51%).

[0336] LC-MS: [M+H] + :293.0.

[0337] Synthesis of 5-(hydroxymethyl)-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile 11c:

[0338]

[0339] 5-Formyl-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile 11b (1.0 g, 3.42 mmol) was dissolved in methanol (20 mL), cooled to 0°C, and sodium borohydride (194.1 mg, 5.13 mmol) was slowly added. The reaction was stirred at room temperature for 2 h, and water (10 mL) was added to quench the reaction. The solvent was concentrated under reduced pressure and extracted with ethyl acetate (20 mL x 3). The organic phases were combined, washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and concentrated to give compound 11c (1.0 g, 99%) as a white solid.

[0340] LC-MS: [M+H] + :295.0.

[0341] Compound 11: Synthesis of 5-((7-oxo-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-9-yl)oxy)methyl)-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile:

[0342]

[0343] 5-(Hydroxymethyl)-2-((2-(trifluoromethyl)pyridin-4-yl)oxy)benzonitrile 11c (50.0 mg, 0.17 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (38.7 mg, 0.17 mmol), cesium carbonate (110.8 mg, 0.34 mmol), methanesulfonic acid (4,5-bisdiphenylphosphino-9,9-dimethylxanthene) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (19.0 mg, 0.02 mmol) were dissolved in 1,4-dioxane (5 mL), replaced with nitrogen three times, and stirred at 100°C for 2 h. The reaction solution was filtered and concentrated, and the residue was prepared by reverse phase (formic acid system) to obtain white solid compound 11 (8.1 mg, 10%).

[0344] LC-MS: [M+H] + :486.0.

[0345] 1H NMR (400MHz, CDCl3) δ8.66(d,J=5.6Hz,1H),7.77(s,1H),7.74(d,J=8.4Hz,1H),7.30(d,J=2.4Hz,1H),7.17(d,J=8.4Hz,1H), 7.05(dd,J=5.6,2.4Hz,1H),5.54(s,2H),4.81(s,2H),4.68(s,2H),4.06-3.96(m,2H),3.39-3.31(m,2H),2.23-2.12(m,2H).

[0346] Embodiment 9:

[0347] Compound 12: 9-(4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0348]

[0349] Synthesis of 4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzaldehyde 12b:

[0350]

[0351] Compound 4-chloro-3-(trifluoromethyl)phenol 12a (25.0 g, 127.19 mmol), 3,4,5-trifluorobenzaldehyde (20.4 g, 127.19 mmol) and potassium carbonate (26.4 g, 190.79 mmol) were dissolved in N,N-dimethylformamide (200 mL), replaced with nitrogen three times, and slowly heated to 90°C for 4 hours. The reaction solution was filtered and concentrated under reduced pressure to remove N,N-dimethylformamide, and the residue was purified by column (petroleum ether: ethyl acetate = 8:1) to obtain yellow solid compound 12b (28.5 g, 67%).

[0352] Synthesis of (4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorophenyl)methanol 12c:

[0353]

[0354] Compound 4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzaldehyde 12b (1.0 g, 2.97 mmol) was dissolved in methanol (15 mL), cooled to 0°C, sodium borohydride (0.17 g, 4.46 mmol) was slowly added, and the temperature was slowly restored to room temperature for 3 h. Saturated ammonium chloride solution was added dropwise at 0°C, and the methanol was removed by concentration under reduced pressure. The mixture was extracted with ethyl acetate (20 mL x 3), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column (petroleum ether: ethyl acetate = 8:1) to obtain white solid compound 12c (710.0 mg, 71%).

[0355] Compound 12: Synthesis of 9-(4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorobenzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0356]

[0357] Compound 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol), (4-(4-chloro-3-(trifluoromethyl)phenoxy)-3,5-difluorophenyl)methanol 12c (81.8 mg, 0.24 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bisdiphenylphosphinothrene) (2'-amino-1,1'-biphenyl-2-yl) palladium (II) (20.8 mg, 0.02 mmol) and cesium carbonate (143.1 mg, 0.44 mmol) were dissolved in dioxane (10 mL), replaced with nitrogen three times, and the temperature was raised to 100 ° C for reaction for 2 h. The reaction solution was filtered and the filtrate was concentrated under reduced pressure. The residue was freeze-dried by reverse phase preparation (formic acid system) to obtain white solid compound 12 (16.6 mg, 14%).

[0358] LC-MS: [M+H] + :530.0.

[0359] 1 H NMR (400MHz, CDCl3) δ7.41(d,J=8.8Hz,1H),7.30(d,J=2.8Hz,1H),7.08-6.99(m,3H),5.40(s, 2H),4.77(s,2H),4.68(s,2H),3.99(t,J=6.0Hz,2H),3.33(t,J=6.0Hz,2H),2.17-2.12(m,2H).

[0360] Embodiment 10:

[0361] Compound 13: 9-((3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0362]

[0363] Synthesis of 3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)benzaldehyde 13b:

[0364]

[0365] 2-Methylpyridin-4-ol 13a (25.0 g, 229.06 mmol), 3,4,5-trifluorobenzaldehyde (40.3 g, 251.99 mmol) and potassium carbonate (47.5 g, 343.63 mmol) were dissolved in N,N-dimethylformamide (300 mL), replaced with nitrogen three times, slowly heated to 90°C, and stirred for 3 hours. The reaction solution was filtered, the filter cake was washed with ethyl acetate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a yellow oily product compound 3b (19.0 g, 33%).

[0366] LC-MS: [M+H] + :250.4.

[0367] Synthesis of (3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)phenyl)methanol 13c:

[0368]

[0369] 3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)benzaldehyde 3b (18.0 g, 72.23 mmol) was dissolved in methanol (200 mL), cooled to 0°C, sodium borohydride (4.1 g, 108.34 mmol) was slowly added, and the temperature was slowly restored to room temperature for 2 h. Saturated ammonium chloride solution (200 mL) was added dropwise at 0°C to quench the reaction, the solvent was concentrated under reduced pressure, extracted with ethyl acetate (200 mL x 2), the organic phases were combined, and dried over anhydrous sodium sulfate, and the residue was purified by column (petroleum ether: ethyl acetate = 7:1) to obtain white solid compound 13c (14.0 g, 77%).

[0370] Compound 13: Synthesis of 9-((3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0371]

[0372] 9-Chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol), (3,5-difluoro-4-((2-methylpyridin-4-yl)oxy)phenyl)methanol 13c (60.7 mg, 0.24 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (20.8 mg, 0.02 mmol) and cesium carbonate (143.1 mg, 0.44 mmol) were dissolved in dioxane (10 mL), replaced with nitrogen three times, and heated to 100 °C for 2 h. The reaction solution was concentrated and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane:methanol=10:1) to obtain white solid compound 13 (14.4 mg, 15%).

[0373] LC-MS: [M+H] + :443.4.

[0374] 1 H NMR (400MHz, CDCl3) δ8.37(d,J=5.6Hz,1H),7.05(d,J=8.0Hz,2H),6.69(d,J=2.0Hz,1H),6.66(dd,J=5.6,2.0Hz,1H) ,5.41(s,2H),4.77(s,2H),4.69(s,2H),3.99(t,J=6.0Hz,2H),3.33(t,J=6.0Hz,2H),2.52(s,3H),2.18-2.12(m,2H).

[0375] Embodiment 11:

[0376] Compound 14: 9-((3,4,5-trifluorobenzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0377]

[0378] Compound 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthran-7-one 1h (50.0 mg, 0.22 mmol) was dissolved in N,N-dimethylformamide (5 mL), (3,4,5-trifluorophenyl)methanol (71.3 mg, 0.44 mmol) and cesium carbonate (215.0 mg, 0.66 mmol) were added, and the mixture was stirred at room temperature for 2 h. Water (10 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (30 mL x 2), the organic layers were combined, washed with saturated sodium chloride (30 mL x 1), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated, and the residue was purified by column chromatography (methanol: dichloromethane = 1:5), and then concentrated and freeze-dried to obtain white solid compound 14 (15.0 mg, 19%).

[0379] LC-MS: [M+H] + :354.0.

[0380] 1 H NMR (400MHz, CDCl3) δ7.03-7.00(m,2H),5.41(s,2H),4.79(s,2H),4.64(s,2H),3.99-3.97(m,2H),3.34(t,J=5.6Hz,2H),2.19-2.12(m,2H).

[0381] Embodiment 12:

[0382] Compound 15: 9-((2,3-difluorobenzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0383]

[0384] Dissolve the compound 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol) in N,N-dimethylformamide (5 mL), add (2,3-difluorophenyl)methanol (63.4 mg, 0.44 mmol), cesium carbonate (143.4 mg, 0.44 mmol) and methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium (II) (19.0 mg, 0.02 mmol). Replace with nitrogen three times, heat to 100°C, and stir to react for 2 hours. Cool to room temperature, filter, concentrate, add water (10 mL) to the residue, extract with ethyl acetate (10 mL x 3), combine the organic layers and wash with saturated brine (30 mL x 1), dry the organic phase with anhydrous sodium sulfate, filter, concentrate, and the residue is analyzed by Prep-TLC (dichloromethane: methanol = 15: 1) to obtain a white solid product compound 15 (12.5 mg, 17%). LC-MS: [M+H] + :336.0.

[0385] 1 H NMR (400MHz, CDCl3) δ7.21-7.02(m,3H),5.46(s,2H),4.74(s,2H),4.61(s,2H),3.97(t,J=6.0Hz,2H),3.30(t,J=6.0Hz,2H),2.16-2.10(m,2H).

[0386] Embodiment 13:

[0387] Compound 16: 9-((3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0388]

[0389] Synthesis of 3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)benzaldehyde 16b:

[0390]

[0391] Compound 1-methyl-1H-pyrazol-4-ol 16a (900.0 mg, 9.17 mmol), 3,4,5-trifluorobenzaldehyde (1.5 g, 9.17 mmol), potassium carbonate (1.9 g, 13.76 mmol) were dissolved in N,N-dimethylformamide (20 mL), heated to 90°C, and stirred for 2 h. The reaction solution was cooled and filtered, extracted with water (10 mL) and ethyl acetate (10 mL x 2), the organic layers were combined, washed with saturated brine (10 mL x 1), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:2) to obtain white solid compound 16b (1.6 g, 73%) after concentration.

[0392] LC-MS: [M+H] + :239.0.

[0393] Synthesis of (3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)phenyl)methanol 16c:

[0394]

[0395] Compound 3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)benzaldehyde 16b (1.5 g, 6.30 mmol) was dissolved in tetrahydrofuran (20 mL), cooled to 0°C, sodium borohydride (357.5 mg, 9.45 mmol) was slowly added, warmed to room temperature, and stirred for 1 h. Saturated ammonium chloride (10 mL) was added dropwise to quench the reaction, and water (10 mL) and ethyl acetate (20 mL x 2) were added for extraction. The organic layers were combined and washed with saturated brine (10 mL x 1). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (ethyl acetate: petroleum ether = 1:1) to obtain white solid compound 16c (1.1 g, 73%) after concentration. LC-MS: [M+H] + :241.0.

[0396] Compound 16: Synthesis of 9-((3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0397]

[0398] Compound (3,5-difluoro-4-((1-methyl-1H-pyrazol-4-yl)oxy)phenyl)methanol 16c (50.0 mg, 0.21 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (47.8 mg, 0.21 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)) (19.0 mg, 0.02 mmol), and cesium carbonate (101.0 mg, 0.31 mmol) were dissolved in dioxane (5 mL), replaced with nitrogen three times, heated to 100°C, and stirred for reaction for 2 h. The solvent was concentrated to dryness, and water (10 mL) and ethyl acetate (10 mL x 2) were added for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and prepared for separation (formic acid system). After freeze-drying, white solid compound 16 (18.1 mg, 20%) was obtained. LC-MS: [M+H] + :432.0.

[0399] 1 H NMR(400MHz, CDCl3)δ7.26(s,1H),7.17(s,1H),7.00-6.95(m,2H),5.33(s,2H),4.75(s,2H) ,4.65(s,2H),3.97(t,J=6.0Hz,2H),3.80(s,3H),3.31(t,J=6.0Hz,2H),2.21-2.10(m,2H).

[0400] Embodiment 14:

[0401] Compound 17: 9-((3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenan-7(1H)-one

[0402]

[0403] Synthesis of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole 17b:

[0404]

[0405] 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 17a (24.0 g, 123.69 mmol), 1,1,1-trifluoro-2-iodoethane (27.3 g, 129.87 mmol) and cesium carbonate (44.3 g, 136.05 mmol) were dissolved in N,N-dimethylformamide (200 mL), replaced with nitrogen three times, slowly heated to 80°C, and reacted for 18 hours. The reaction solution was filtered, water (200 mL) was added, and washed with ethyl acetate (200 mL x 3), the organic phases were combined, and purified by column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain a colorless oil compound 17b (5.0 g, 15%).

[0406] LC-MS: [M+H] + :277.4.

[0407] Synthesis of 1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-ol 17c:

[0408]

[0409] 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole 17b (5.0 g, 18.11 mmol) was dissolved in tetrahydrofuran (100 mL), cooled to 0°C, and hydrogen peroxide (4.4 g, 110.72 mmol) and sodium hydroxide solution (3M, 12.9 mL, 38.88 mmol) were slowly added, and the mixture was returned to room temperature for 4 h. Saturated sodium sulfite solution (100 mL) was added to the reaction solution, and 1M HCl solution was added dropwise at 0°C to adjust the pH to 4-5, and the mixture was extracted three times with ethyl acetate (120 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column (petroleum ether: ethyl acetate = 6:1) to obtain compound 17c (2.6 g, 86%) as a colorless oil.

[0410] LC-MS: [M+H] + :167.0.

[0411] Synthesis of 3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)benzaldehyde 17d:

[0412]

[0413] Compound 1-(2,2,2-trifluoroethyl)-1H-pyrazole-4-ol 17c (2.6 g, 15.65 mmol), 3,4,5-trifluorobenzaldehyde (2.5 g, 15.65 mmol) and potassium carbonate (3.2 g, 23.48 mmol) were dissolved in N,N-dimethylformamide (50 mL), replaced with nitrogen three times, and slowly heated to 90°C for 2 h. The reaction solution was concentrated and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a white solid compound 17d (2.9 g, 61%).

[0414] LC-MS: [M+H] + :307.3.

[0415] Synthesis of (3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)phenyl)methanol 17e:

[0416]

[0417] Compound 3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)benzaldehyde 17d (2.8 g, 9.15 mmol) was dissolved in methanol (30 mL), cooled to 0°C, sodium borohydride (0.5 g, 13.72 mmol) was slowly added, and the temperature was slowly restored to room temperature for 3 h. Saturated aqueous ammonium chloride solution (30 mL) was added dropwise at 0°C, the reaction solution was concentrated under reduced pressure, extracted with ethyl acetate (30 mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain white solid compound 17e (1.5 g, 53%).

[0418] LC-MS: [M+H] + :309.4.

[0419] Compound 17: Synthesis of 9-((3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxy-3a,6a,8-triazaphenan-7(1H)-one:

[0420]

[0421] (3,5-difluoro-4-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)oxy)phenyl)methanol 17e (67.7 mg, 0.22 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (20.8 mg, 0.02 mmol) and cesium carbonate (143.1 mg, 0.44 mmol) were dissolved in dioxane (10 mL), replaced with nitrogen three times, and heated to 100 °C for 2 h. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was prepared by reverse phase (formic acid system) and freeze-dried to obtain white solid compound 17 (13.3 mg, 12%).

[0422] LC-MS: [M+H] + :500.2.

[0423] 1 H NMR(400MHz, CDCl3)δ7.40(s,1H),7.30(s,1H),7.02-6.97(m,2H),5.36(s,2H),4.76(s,2H),4.6 6(s,2H),4.59(q,J=8.4Hz,2H),3.98(t,J=5.6Hz,2H),3.32(t,J=6.0Hz,2H),2.17-2.11(m,2H).

[0424] Embodiment 15:

[0425] Compound 18: 9-((3,5-difluoro-4-(3-(trifluoromethoxy)phenoxy)benzyl)oxy)-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0426]

[0427] Synthesis of 3,5-difluoro-4-(3-(trifluoromethoxy)phenoxy)formaldehyde 18b:

[0428]

[0429] 3-(Trifluoromethoxy)phenol 18a (25.0 g, 140.36 mmol), 3,4,5-trifluorobenzene-1-carboxaldehyde (22.5 g, 140.36 mmol), potassium carbonate (29.1 g, 210.54 mmol) were dissolved in N,N-dimethylformamide (400 mL) and stirred at 90°C for 2 h. Water (200 mL) was added, and the reaction solution was extracted with ethyl acetate (200 mL x 3), the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain a colorless oil compound 18b (25.0 g, 56%).

[0430] Synthesis of (3,5-difluoro-4-(3-(trifluoromethoxy)phenoxy)phenyl)methanol 18c:

[0431]

[0432] 3,5-Difluoro-4-(3-(trifluoromethoxy)phenoxy)formaldehyde 18b (25.0 g, 78.57 mmol) was dissolved in methanol (400 mL), sodium borohydride (4.5 g, 117.85 mmol) was added to the mixture at 0°C, and stirred at room temperature for 2 h. The reaction solution was quenched with water (100 mL), extracted with ethyl acetate (100 mL x 3), the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 1:1) to give colorless oil compound 18c (20.0 g, 79%).

[0433] Compound 18: Synthesis of 9-((3,5-difluoro-4-(3-(trifluoromethoxy)phenoxy)benzyl)oxy)-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0434]

[0435] Compound (3,5-difluoro-4-(3-(trifluoromethoxy)phenoxy)phenyl)methanol 18c (70.4 mg, 0.22 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bisdiphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium (II) (19.0 mg, 0.02 mmol), cesium carbonate (143.4 mg, 0.44 mmol) were dissolved in dioxane (10 mL), replaced with nitrogen 3 times, heated to 100°C, and stirred for 2 h. The crude product was separated by reverse phase preparative separation (formic acid system), and freeze-dried to obtain white solid compound 18 (23.0 mg, 20%). LC-MS: [M+H] + :512.3.

[0436] 1 H NMR (400MHz, CDCl3) δ7.33-7.28(m,1H),7.07-7.02(m,2H),6.94(d,J=8.0Hz,1H),6.86-6.83(m,2H ),5.40(s,2H),4.77(s,2H),4.68(s,2H),4.00-3.97(m,2H),3.34-3.31(m,2H),2.17-2.12(m,2H).

[0437] Embodiment 16:

[0438] Compound 19: 9-((3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0439]

[0440] Synthesis of 4-(benzyloxy)-2-(trifluoromethoxy)pyridine 19b:

[0441]

[0442] Compound 4-(benzyloxy)pyridin-2-ol 19a (1.0 g, 4.97 mmol) and 1-(trifluoromethyl)-1,2-benzimidoyl-3(1H)-one (1.6 g, 4.97 mmol) were dissolved in nitromethane (25 mL), replaced with nitrogen three times, heated to 100°C, and reacted for 18 hours. The reaction solution was concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate = 10:1) to obtain a colorless oil compound 19b (540 mg, 40%).

[0443] LC-MS: [M+H] + :270.4.

[0444] Synthesis of 2-(trifluoromethoxy)pyridin-4-ol 19c:

[0445]

[0446] 4-(Benzyloxy)-2-(trifluoromethoxy)pyridine 19b (340.0 mg, 1.26 mmol) and palladium carbon (10%, 81.0 mg) were dissolved in methanol (10 mL) and stirred at 60°C under 3 MPa hydrogen pressure for 18 h. The reaction solution was filtered, concentrated, and purified by column chromatography (petroleum ether: ethyl acetate = 6:1) to obtain compound 19c (170.0 mg, 75%) as a white solid.

[0447] LC-MS: [M+H] + :180.4.

[0448] Synthesis of 3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)benzaldehyde 19d:

[0449]

[0450] Compound 2-(trifluoromethoxy)pyridin-4-ol 19c (260.0 mg, 1.45 mmol), 3,4,5-trifluorobenzaldehyde (232.4 mg, 1.45 mmol) and potassium carbonate (300.9 mg, 2.18 mmol) were dissolved in N,N-dimethylformamide (8 mL), replaced with nitrogen three times, and slowly heated to 90°C for 4 hours. The reaction solution was filtered and concentrated under reduced pressure to remove N,N-dimethylformamide, and the residue was purified by column (petroleum ether: ethyl acetate = 5:1) to obtain a colorless oil compound 19d (300.0 mg, 65%).

[0451] LC-MS: [M+H] + :320.0.

[0452] Synthesis of (3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)phenyl)methanol 19e:

[0453]

[0454] Compound 3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)benzaldehyde 19d (300.0 mg, 0.94 mmol) was dissolved in methanol (10 mL), cooled to 0°C, sodium borohydride (53.3 mg, 1.41 mmol) was slowly added, and the temperature was slowly restored to room temperature for 2 h. Saturated aqueous ammonium chloride solution (30 mL) was added dropwise at 0°C, the reaction solution was concentrated under reduced pressure, and extracted three times with ethyl acetate (30 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the residue was purified by column (petroleum ether: ethyl acetate = 5:1) to obtain compound 19e (160 mg, 53%) as a white solid.

[0455] LC-MS: [M+H] + :322.0.

[0456] Compound 19: Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0457]

[0458] (3,5-difluoro-4-((2-(trifluoromethoxy)pyridin-4-yl)oxy)phenyl)methanol 19e (70.6 mg, 0.22 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0 mg, 0.22 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (20.8 mg, 0.02 mmol) and cesium carbonate (143.1 mg, 0.44 mmol) were dissolved in dioxane (5 mL), replaced with nitrogen three times, and the temperature was slowly raised to 100°C for 2 h. The reaction solution was filtered and the filtrate was concentrated under reduced pressure. The residue was prepared by reverse phase (formic acid system) to obtain compound 19 (25.0 mg, 22%) as a white solid.

[0459] LC-MS: [M+H] + :513.0.

[0460] 1H NMR (400MHz, CDCl3) δ8.21(d,J=6.0Hz,1H),7.08(d,J=8.0Hz,2H),6.81(dd,J=5.6,2.0Hz,1H),6.50(d,J=2.4H z,1H),5.41(s,2H),4.78(s,2H),4.69(s,2H),3.99(t,J=6.0Hz,2H),3.33(t,J=6.0Hz,2H),2.18-2.12(m,2H).

[0461] Embodiment 17:

[0462] Compound 20: 9-((3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0463]

[0464] Synthesis of 3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzaldehyde 20b:

[0465]

[0466] Compound 6-(trifluoromethyl)pyridin-3-ol 20a (5.0 g, 30.66 mmol), 3,4,5-trifluorobenzaldehyde (4.9 g, 30.66 mmol), potassium carbonate (6.4 g, 45.98 mmol) were dissolved in N,N-dimethylformamide (100 mL) and stirred at 90°C for 2 h. Water (50 mL) was added, and the reaction solution was extracted with ethyl acetate (50 mL x 3), the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain a colorless oil compound 20b (5.0 g, 54%).

[0467] LC-MS: [M+H] + :304.0.

[0468] Synthesis of (3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)phenyl)methanol 20c:

[0469]

[0470] Compound 3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzaldehyde 20b (5.0 g, 16.49 mmol) was dissolved in methanol (100 mL), sodium borohydride (935.73 mg, 24.74 mmol) was added to the mixture at 0°C, and stirred at room temperature for 2 h. The reaction solution was quenched with water (50 mL), extracted with ethyl acetate (50 mL x 3), the organic phases were combined, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain compound 20c (4.0 g, 79%) as a colorless oil.

[0471] LC-MS: [M+H] + :306.0.

[0472] Compound 20: Synthesis of 9-((3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0473]

[0474] Compound (3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)phenyl)methanol 20c (50.0 mg, 0.16 mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (37.3 mg, 0.16 mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)) (15.5 mg, 0.02 mmol), and cesium carbonate (106.8 mg, 0.33 mmol) were dissolved in dioxane (5 mL), replaced with nitrogen three times, and heated to 100°C and stirred for 2 h. The reaction mixture was cooled and filtered, and water (10 mL) and ethyl acetate (30 mL x 2) were added to extract the reaction solution. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (methanol: dichloromethane = 1:10). After concentration, white solid compound 20 (25.2 mg, 31%) was obtained.

[0475] LC-MS: [M+H] + :497.0.

[0476] 1H NMR (400MHz, CDCl3) δ8.48(d,J=2.8Hz,1H),7.62(d,J=8.8Hz,1H),7.27(dd,J=8.8,2.4Hz,1H),7.09-7.04(m ,2H),5.40(s,2H),4.76(s,2H),4.67(s,2H),3.97(t,J=6.0Hz,2H),3.31(t,J=5.6Hz,2H),2.16-2.10(m,2H).

[0477] Embodiment 18:

[0478] Compound 21: 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one

[0479]

[0480] Synthesis of 3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)benzaldehyde 21b:

[0481]

[0482] 2-(Trifluoromethyl)pyrimidin-5-ol 21a (1.0 g, 6.09 mmol), 3,4,5-trifluorobenzaldehyde (1.2 g, 7.31 mmol), potassium carbonate (1.1 g, 7.92 mmol) were dissolved in N,N-dimethylformamide (15 mL) and stirred at 90°C for 2 h. The reaction solution was filtered, the filter cake was washed with ethyl acetate, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain yellow solid compound 21b (1.1 g, 59%).

[0483] LC-MS: [M+H] + :305.0.

[0484] Synthesis of (3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)phenyl)methanol 21c:

[0485]

[0486] 3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)benzaldehyde 21b (950.0 mg, 3.12 mmol) was dissolved in methanol (10 mL), cooled to 0°C, and sodium borohydride (118.0 mg, 3.12 mmol) was slowly added. The reaction was stirred at this temperature for 0.5 h, and water (10 mL) was added dropwise to quench the reaction. The solvent was concentrated under reduced pressure, extracted with ethyl acetate (10 mL x 2), washed with saturated brine (10 mL x 1), dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The residue was purified by column chromatography (petroleum ether: ethyl acetate = 3:1) to give an off-white solid compound 21c (700 mg, 73%).

[0487] LC-MS: [M+H] + :307.4.

[0488] Compound 21: Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)benzyl)oxy-3,4,5,6-tetrahydro-2-oxo-3a,6a,8-triazaphenanthran-7(1H)-one:

[0489]

[0490] Compound (3,5-difluoro-4-((2-(trifluoromethyl)pyrimidin-5-yl)oxy)phenyl)methanol 21c (67.30.22mmol), 9-chloro-5,6-dihydro-1H,3H,4H,7H-2-oxo-3a,6a,8-triazaphenanthren-7-one 1h (50.0mg, 0.22mmol), methanesulfonic acid (9,9-dimethyl-4,5-bis(diphenylphosphinothrene)(2'-amino-1,1'-biphenyl-2-yl)palladium(II)) (19.0mg, 0.02mmol), and cesium carbonate (143.4mg, 0.44mmol) were dissolved in dioxane (10mL), replaced with nitrogen three times, heated to 100°C, and stirred for reaction for 2h. The crude product was separated by reverse phase preparative separation (formic acid system) and freeze-dried to obtain white solid compound 21 (32 mg, 29%). LC-MS: [M+H] + :498.3.

[0491] 1 H NMR(400MHz, CDCl3)δ8.56(s,2H),7.14-7.09(m,2H),5.42(s,2H),4.78(s,2H) ,4.68(s,2H),3.99(t,J=6.0Hz,2H),3.33(t,J=6.0Hz,2H),2.18-2.12(m,2H).

[0492] Embodiment 19:

[0493] Compound 22: 9-((3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)benzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0494]

[0495] Synthesis of 3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)benzaldehyde 22b:

[0496]

[0497] Compound 2-(trifluoromethyl)quinolin-7-ol 22a (1.0 g, 4.69 mmol), 3,4,5-trifluorobenzaldehyde (900.0 mg, 5.63 mmol) and potassium carbonate (1.3 g, 9.38 mmol) were dissolved in N,N-dimethylformamide (15.0 mL), and the mixture was stirred at 90°C for 9 hours. After the reaction was completed, the reaction solution was diluted with water, extracted twice with ethyl acetate, the combined organic phases were washed with saturated brine, the obtained organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo, and the obtained crude product was purified by silica gel chromatography (dichloromethane: methanol = 20: 1) to obtain white solid compound 22b (1.2 g, 75%).

[0498] LC-MS: [M+H] + :354.0.

[0499] Synthesis of (3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)phenyl)methanol 22c:

[0500]

[0501] Compound 3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)benzaldehyde 22b (1.2 g, 3.39 mmol) was dissolved in ethanol (20.0 mL), cooled to 0°C, sodium borohydride (190.0 mg, 4.07 mmol) was added, and the mixture was stirred at 25°C for 3 hours. After the reaction was completed, aqueous ammonium chloride was added to quench, the mixture was concentrated in vacuo, and the crude product was purified by silica gel chromatography (dichloromethane: methanol = 10: 1) to give white solid compound 22c (0.8 g, 67%).

[0502] LC-MS: [M+H] + :356.0.

[0503] Compound 22: Synthesis of 9-((3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)benzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0504]

[0505] (3,5-difluoro-4-((2-(trifluoromethyl)quinolin-7-yl)oxy)phenyl)methanol 22c (250.0 mg, 0.70 mmol), compound 1h (191.8 mg, 0.85 mmol), cesium carbonate (459.2 mg, 1.41 mmol) and methanesulfonic acid (4,5-bisdiphenylphosphino-9,9-dimethylxanthene) (2-amino-1,1'-biphenyl-2-yl) palladium (II) (66.9 mg, 0.07 mmol) were dissolved in 1,4-dioxane (23.0 mL), the gas in the bottle was replaced with nitrogen, and the mixture was stirred at 100°C for 2 hours. After the reaction was completed, the temperature was lowered to room temperature, and water (30.0 mL) was added to the resulting mixture for dilution, and then extracted twice with ethyl acetate (30.0 mL), the organic phases were combined and washed with saturated brine (60.0 mL), and then the organic layer was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain a crude oil. The crude product was purified by silica gel chromatography (dichloromethane: methanol = 10: 1) to obtain a white solid compound 22 (57.8 mg, 15%).

[0506] LC-MS: [M+H] + :547.1.

[0507] 1 H NMR (400MHz, DMSO-d6) δ8.74(d,J=8.5Hz,1H),8.26(d,J=9.1Hz,1H),7.92(d,J=8.5Hz,1H),7.74(dd,J=9.1,2.6Hz,1H),7.44(d,J=8.8Hz, 2H),7.31(d,J=2.3Hz,1H),5.36(s,2H),4.80(s,2H),4.64(s,2H),3.78-3.73(m,2H),3.28(t,J=5.8Hz,2H),2.02(dd,J=11.8,5.9Hz,2H).

[0508] Embodiment 20:

[0509] Compound 23: 9-(3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)benzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one

[0510]

[0511] Synthesis of 3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)benzaldehyde 23b:

[0512]

[0513] Compound 3-(pentafluorosulfanyl)phenol 23a (1.80 g, 8.20 mmol) and 3,4,5-trifluorobenzaldehyde (1.97 g, 12.30 mmol) were dissolved in N,N-dimethylformamide (54 mL), potassium carbonate (3.40 mg, 24.60 mmol) was added to the mixture, and the mixture was stirred at 90°C for 1 hour. After the reaction was completed, the mixture was diluted with water, extracted twice with ethyl acetate, and the organic phases were combined. The organic phases were washed twice with saturated brine and dried over anhydrous sodium sulfate. The organic phases were concentrated under reduced pressure, and the crude product was purified by silica gel chromatography (ethyl acetate: petroleum ether = 10:1) to obtain yellow oil compound 23b (2.0 g, 68%). LC-MS: [M+Na] + :383.3.

[0514] Synthesis of (3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)phenyl)methanol 23c:

[0515]

[0516] Compound 3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)benzaldehyde 23b (2.0 g, 5.60 mmol) was dissolved in ethanol (40.0 mL), sodium borohydride (0.25 g, 6.72 mmol) was added to the mixture, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the crude product was purified by silica gel chromatography (ethyl acetate: petroleum ether = 1:1) to obtain yellow oil compound 23c (1.4 g, 70%).

[0517] LC-MS: [M+Na] + :385.3.

[0518] Compound 23: Synthesis of 9-(3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)benzyl)oxy)-5,6-dihydro-1H,3H,4H,7H-2-oxa-3a,6a,8-triazaphenanthran-7-one:

[0519]

[0520] Compound 1h (60.0 mg, 0.26 mmol), (3,5-difluoro-4-(3-(pentafluorosulfanyl)phenoxy)phenyl)methanol 23c (112.0 mg, 0.31 mmol), methanesulfonic acid (4,5-bisdiphenylphosphino-9,9-dimethylxanthene) (2-amino-1,1'-biphenyl-2-yl)palladium (II) (18.0 mg, 0.02 mmol) and cesium carbonate (169.0 mg, 0.52 mmol) were dissolved in dioxane (3.0 mL), and the mixture was stirred at 100° C. for 3 hours. After the reaction was completed, the reaction solution was concentrated in vacuo, and the crude product was purified by silica gel chromatography (dichloromethane) to obtain white solid compound 23 (13.8 mg, 9%).

[0521] LC-MS: [M+H] + :553.9.

[0522] 1 H NMR (400MHz, DMSO-d6) δ7.69(dd,J=8.1,1.7Hz,1H),7.65-7.58(m,2H),7.40(d,J=8.9Hz,2H),7.25(d,J=8.3 Hz,1H),5.33(s,2H),4.80(s,2H),4.62(s,2H),3.78-3.69(m,2H),3.27(d,J=5.8Hz,2H),2.02-1.98(m,2H).

[0523] Biological evaluation

[0524] 1. Recombinant human Lp-PLA2 inhibition assay (rhLp-PLA2)

[0525] Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), hydrolyzes 2-thio-PAF, and its product reacts with DTNB to generate 5-thio-2-Nitrobenzoic Acid again; this substance has a certain absorption of 414nm light waves, and based on this, an experimental method is set up to detect the inhibitory effect of the compound on the activity of LP-PLA2 in plasma.

[0526] 1. Prepare assay buffer: 50 mM MES (pH 6.5), 150 mM NaCl, 0.1% BSA

[0527] 2. Dissolve the compound powder in DMSO to a 10 mM stock solution and keep at room temperature for later use.

[0528] 3. The compound solution was diluted four-fold with DMSO.

[0529] 4. Use Echo to transfer serial dilutions of compounds to 384-well plate experiments.

[0530] 5. Prepare 2x PLA2G7 in assay buffer.

[0531] 6. Add 15 μl of prepared PLA2G7 to the 384-well plate and place it in a 25°C incubator for incubation.

[0532] 7. Prepare a 2x mixture of 2-Thio-PAF and DTNB in ​​assay buffer.

[0533] 8. Add 15 μl of the mixture of 2x 2-Thio-PAF and DTNB to the plate and incubate in a 25°C incubator.

[0534] 9. Data was read using Envision, ABS 405nm. The results are listed in Table 1.

[0535] Table 1

[0536] Compound No. <![CDATA[rhLp-PLA2(IC 50 ,nM)]]> Compound 1 (Example 1) 0.99 Compound 2 (Example 2) 2.3 Compound 3 (Example 3) 0.8 Compound 4 (Example 4) 0.5 Compound 5 (Example 4) 0.4 Compound 6 (Example 5) 8.6 Compound 7 (Example 5) 1.6 Compound 8 (Example 6) 0.9 Compound 9 (Example 6) 1.1 Compound 10 (Example 7) 3.0 Compound 11 (Example 8) 2.9 Compound 12 (Example 9) 0.4 Compound 13 (Example 10) 54.0 Compound 14 (Example 11) 53.7 Compound 15 (Example 12) 146.4 Compound 16 (Example 13) 265.6 Compound 17 (Example 14) 76.6 Compound 18 (Example 15) 2.0 Compound 19 (Example 16) 0.8 Compound 20 (Example 17) 4.4 Compound 21 (Example 18) 5.9 Compound 22 (Example 19) 3.0 Compound 23 (Example 20) 4.0 Darapladib 0.52

[0537] Experimental reagents:

[0538] PLA2G7 (Sino biological, 10848-H08H); 2-Thio-PAF (Cayman, 60945); DTNB (Sigma, D-8130);

[0539] II: Human plasma Lp-PLA2 inhibition assay

[0540] Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), hydrolyzes 2-thio-PAF, and its product reacts with DTNB to generate 5-thio-2-Nitrobenzoic Acid again; this substance has a certain absorption of 414nm light waves, and based on this, an experimental method is set up to detect the inhibitory effect of the compound on the activity of LP-PLA2 in plasma.

[0541] Determination method:

[0542] 1. Dilute the test compound with DMSO at a gradient ratio of 1:2; then dilute with Assay Buffer (0.1MTris-HCl, pH 7.5; 0.1mg / ml BSA) at a ratio of 1:99; mix well;

[0543] 2. Take a 96-well transparent plate and use a multi-well pipette to add 8 μl of 1 mM DTNB, 8 μl of the diluted test compound, and 4 μl of human plasma to the 96-well plate. Mix well and centrifuge (500 g, room temperature, 5 min). Place in a 37°C constant temperature incubator and incubate for 30 min. Then transfer to a 25°C constant temperature incubator.

[0544] 3. After 15 min, add 60 μl of 133.33 μM 2-thio-PAF using a multi-well pipette and mix well; centrifuge (500 g, room temperature, 5 min);

[0545] 4. Set the parameters of the microplate reader (Abs414, time interval 1min, recording for 40min).

[0546] 5. The exported data were processed and analyzed using GraphPad Prism7. The results are listed in Table 2.

[0547] Table 2

[0548]

[0549]

[0550] Experimental reagents:

[0551] Human plasma(PreceDo,20230203EDTA); DTNB(TCI,D0944); 2-thio-PAF(MCE,HY-101263)

[0552] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof, in, n1, n2, n3 are each independently 0, 1 or 2; R1 and R2 are each independently H or alkyl; X1 and X2 are each independently selected from: alkylene, -O-, -S-, or -NR'-; wherein R' is selected from: H, alkyl, deuterated alkyl, or cycloalkyl; Ar is an arylene or heteroarylene group; the arylene or heteroarylene group is optionally substituted by 0, 1 or more substituents, each of which is independently selected from the group consisting of halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, deuterated alkyl, deuterated alkoxy, hydroxy, hydroxyalkyl, cyano, amino, monoalkyl or dialkyl substituted amino, nitro, carboxyl, aldehyde, cycloalkyl, heterocyclyl, aryl, or heteroaryl; Y is -H, halogen, alkyl, haloalkyl, haloalkoxy, cycloalkyl, alkoxy, deuterated alkyl, deuterated alkoxy, hydroxy, hydroxyalkyl, cyano, -OAr', -SAr', -NH-Ar', -NMe-Ar', -NHR", or -R"'-Ar'; wherein Ar' is selected from aryl or heteroaryl; the aryl or heteroaryl is optionally substituted with 0, 1 or more substituents, each of which is independently selected from halogen, alkyl, haloalkyl, alkoxy, hydroxy, hydroxyalkyl, haloalkoxy, deuterated alkyl, deuterated alkoxy, halosulfanyl, cyano, amino, nitro, aldehyde, carboxyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; R" is alkyl or cycloalkyl; R"' is alkylene; Z is O or S; The halogen atoms in the "halogen", "haloalkyl", "haloalkoxy" and "halosulfanyl" are each independently selected from F, Cl, Br or I; The alkyl groups in the aforementioned “alkyl”, “deuterated alkyl”, “deuterated alkoxy”, “hydroxyalkyl”, “haloalkyl”, “haloalkoxy”, “alkoxy”, and “amino substituted with monoalkyl or dialkyl” are each independently C1-C 10 linear or branched alkyl; optionally, C1-C7 linear or branched alkyl; optionally, C1-C4 linear or branched alkyl; optionally, selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, butyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl; The "alkylene" is each independently C1-C 10 A straight or branched alkylene group; optionally, a C1-C7 straight or branched alkylene group; optionally, a C1-C5 straight or branched alkylene group; optionally, selected from methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, tert-butylene, sec-butylene, n-pentylene, 1-methylbutylene, 2-methylbutylene, 3-methylbutylene, isopentylene, 1-ethylpropylene, neopentylene, n-hexylene, 1-methylpentylene, 2-methylpentylene, 3-methylpentylene 1,2-dimethylbutylene, 1,3-dimethylbutylene, 2,3-dimethylbutylene, 2-ethylbutylene, n-heptylene, 2-methylhexylene, 3-methylhexylene, 2,2-dimethylpentylene, 3,3-dimethylpentylene, 2,3-dimethylpentylene, 2,4-dimethylpentylene, 3-ethylpentylene, or 2,2,3-trimethylbutylene; The "cycloalkyl" is C3-C 10 Monocyclic or bicyclic cycloalkyl, optionally, C3-C7 monocyclic cycloalkyl; optionally, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; The "heterocyclic group" is a 3-10-membered non-aromatic heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O and S on the ring; alternatively, the heterocyclic group is a 3-10-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and O on the ring; alternatively, the heterocyclic group is a 3-6-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and O on the ring; alternatively, the heterocyclic group is a 3-10-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and S on the ring; alternatively, the heterocyclic group is a 3-6-membered non-aromatic heterocyclic group containing 1 or 2 heteroatoms selected from N and S on the ring; The "aryl" is a 6-10 membered aryl; optionally, it is phenyl or naphthyl; optionally, it is phenyl, 1-naphthyl, or 2-naphthyl; The "arylene group" is a 6-10 membered arylene group; optionally, it is a phenylene group or a naphthylene group; The "heteroaryl" is a 5-10 membered heteroaromatic ring group containing 1-3 heteroatoms selected from N, O and S on the ring; alternatively, it is a 5-10 membered heteroaromatic ring group containing 1-2 heteroatoms selected from N, O and S on the ring; alternatively, the heteroaromatic ring group is selected from a pyridine ring group, a pyrrole ring group, a pyrimidine ring group, a pyrazine ring group, a pyridazine ring group, a thiophene ring group, or a furan ring group; alternatively, the heteroaromatic group is selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyridazine-3-yl, pyridazine-4-yl, pyrimidine-2-yl, pyrimidine-4-yl, pyrimidine-5-yl, pyrazine yl, pyrazin-3-yl, indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, quinolizinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, naphthyridinyl, quinazolinyl, quinoxalinyl, thieno[2,3-b]furanyl, furano[3,2-b]pyranyl, pyrido[2,3-d]oxazinyl, pyrazolo[4,3-d]oxazolyl, imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, imidazo[1,2-b][1,2,4]triazinyl, benzothiophenyl, benzoxazolyl, benzimidazo[2,3-d]oxazinyl, oxazolyl, benzothiazolyl, benzoxazolinyl, benzoxazinyl, benzofuranyl, benzotriazolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[4,5-b]pyridinyl, imidazo[4,5-c]pyridinyl, pyrazolo[4,3-d]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[3,4-d]pyridinyl, pyrazolo[3,4-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, imidazo[1,2-c]pyrimidinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl, pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl, pyrazolo[2,3-b]pyrazinyl, or pyrimido[4,5-d]pyrimidinyl; optionally, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl; The "heteroarylene" is a 5-10 membered heteroaromatic ring group containing 1-3 heteroatoms selected from N, O and S on the ring; alternatively, it is a 5-10 membered heteroaromatic ring group containing 1-2 heteroatoms selected from N, O and S on the ring; alternatively, the heteroaromatic ring group is selected from a pyridine ring group, a pyrrole ring group, a pyrazole ring group, a pyrimidine ring group, a pyrazine ring group, a pyridazine ring group, a thiophene ring group, or a furan ring group.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, wherein: n1, n2, n3 are each independently 1 or 2; optionally, n1 is 1, optionally, n2 is 1 or 2, optionally, n3 is 1; R1 and R2 are each independently selected from: -H, or C 1-7 Straight or branched alkyl; optionally, -H, or C 1-4 Straight or branched alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, or sec-butyl); Optionally, R1 is -H or -CH3; Optionally, R2 is -H or -CH3; X1 and X2 are each independently selected from: C1-C7 alkylene (optionally, -CH2-, ethylene, n-propylene, isopropylene, n-butylene, or isobutylene), -O-, -S-, or -NR′-; optionally, X1 is -CH2-, or -O-; optionally, X1 is -O-; optionally, X2 is -O-; wherein R′ is selected from -H, C1-C7 alkyl (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl , 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl), deuterated alkyl (optionally, -CD3, -C2D5, or -C3D7), or C3-C6 cycloalkyl (e.g., cyclopropane, cyclobutane, cyclopentane, or cyclohexane); Ar is phenylene or pyridyl, the phenylene or pyridyl is optionally substituted by 0, 1, 2 or 3 substituents, each of which is independently selected from: -F, -Cl, -Br, -I, -CN, -Me, -CF3, -C2H5, -C3H7, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CD3, -OCD3, -OMe, or -OCF3; alternatively, Ar is phenylene, the phenylene is optionally substituted by 1 or 2 substituents, the substituents are -F, or -CN; Y is -H, halogen, methyl, ethyl, n-propyl, isopropyl, -CD3, -OCD3, -CF3, -CHF2, -CH2F, -CH2CF3, -OCF3, -OCHF2, -OCH2F, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -OCH3, -OC2H5, -OC3H7, or -OAr'; Alternatively, Y is -H, -F, -Cl, -Br, -I, or -OAr'; Alternatively, Y is -H, -F, or -OAr'; wherein Ar' is selected from 1, phenyl, pyridyl, pyrimidyl, thienyl, pyrrolyl, pyrazolyl, or quinolyl substituted with 2 or 3 substituents, each of which is independently selected from: -F, -Cl, -Br, -CN, C1-C7 alkyl (optionally methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl butyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 3-ethylpentyl, or 2,2,3-trimethylbutyl), -CD3, -OCD3, C1-C6 haloalkyl, -OCH3, -OC2H7, -OC3H7, C1-C 6-haloalkoxy, halosulfanyl (optionally, fluorosulfanyl or chlorosulfanyl), hydroxy, hydroxyalkyl, cyano, or C3-C6 cycloalkyl (optionally, cyclopropanyl, cyclobutanyl, cyclopentanyl, or cyclohexanyl); optionally, Ar′ is selected from phenyl, pyridin-3-yl, pyridin-4-yl, pyrazol-4-yl, quinolin-7-yl, or pyrimidin-5-yl, optionally substituted with 1 or 2 substituents selected from -F, -Cl, -CH3, -CF3, -CH2CF3, -OCF3, or -SF5; Z is O.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein: n1 is 1, n2 is 1 or 2, and n3 is 1; R1 and R2 are each independently -H or methyl; X1 is -O- or -CH2-, and X2 is -O-; Ar is a phenylene group, and the phenylene group is optionally substituted by 1 or 2 substituents, and the substituents are -F or -CN; Y is -H, -F, or -OAr'; wherein Ar' is phenyl, pyridin-3-yl, pyridin-4-yl, pyrazol-4-yl, quinolin-7-yl, or pyrimidin-5-yl, which is optionally substituted with 1 or 2 substituents selected from -Cl, -CH3, -CF3, -CH2CF3, -OCF3, or -SF5; Z is O.

4. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein the compound of formula (I) is selected from the following compounds:

5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein: The pharmaceutically acceptable salts include anionic salts or cationic salts of the compound of formula (I); Optionally, the pharmaceutically acceptable salt includes an alkali metal salt, an alkaline earth metal salt, or an ammonium salt of the compound of formula (I); optionally, the alkali metal includes sodium, potassium, lithium, or cesium, and the alkaline earth metal includes magnesium, calcium, or strontium; Optionally, the pharmaceutically acceptable salt includes a salt formed by a compound of formula (I) and an organic base; Optionally, the organic base includes trialkylamine, pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-alkylmorpholine, 1,5-diazabicyclo[4.3.0]non-5-ene, 1,8-diazabicyclo[5.4.0]undec-7-ene, or 1,4-diazabicyclo[2.2.2]octane; Optionally, the trialkylamine includes trimethylamine, triethylamine, or N-ethyldiisopropylamine; Optionally, the N-alkylmorpholine includes N-methylmorpholine; Optionally, the pharmaceutically acceptable salt includes a salt formed by a compound of formula (I) and an acid; optionally, the acid includes an inorganic acid or an organic acid; optionally, the inorganic acid includes hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, or carbonic acid; optionally, the organic acid includes formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, glutamic acid, or pamoic acid.

6. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, comprising the following synthetic route 1 or route 2: Route 1: Route 2: In each structural formula, n1, n2, n3, R1, R2, X1, X2, Z, Ar and Y are defined as described in any one of claims 1-5, Pg is a protecting group; optionally, Pg is tert-butyldiphenylsilyl; J is a halogen atom, optionally, J is Cl, Br, or I.

7. A pharmaceutical composition comprising one or more of the compounds of formula (I) or pharmaceutically acceptable salts thereof according to any one of claims 1 to 5 and optionally a pharmaceutically acceptable carrier.

8. The pharmaceutical composition according to claim 7, wherein the dosage form of the pharmaceutical composition comprises an oral preparation, a rectal preparation, or a parenteral preparation; Optionally, the oral preparation includes a solid preparation or a liquid preparation; Optionally, the solid preparation includes a tablet, a powder, a granule, or a capsule; Optionally, the liquid preparation includes an aqueous or oil suspension, or a syrup; Optionally, the preparation for parenteral administration includes a solution for injection, or an aqueous or oily suspension.

9. Use of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 7 or 8 in the preparation of an Lp-PLA2 inhibitor.

10. Use of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, or the pharmaceutical composition according to claim 7 or 8, in the preparation of a medicament for treating neurodegenerative diseases, cardiovascular diseases, diabetic macular edema (DME) or prostate diseases; Optionally, the neurodegeneration-related disease includes Alzheimer's disease (AD), glaucoma, or age-related macular degeneration (AMD); and the cardiovascular disease includes atherosclerosis.